

CASES IN GLOBAL HEALTH DELIVERY

GHD-026 May 2012

Electronic Medical Records at the ISS Clinic in Mbarara, Uganda

In March 2010 Nneka Emenyonu participated in a stakeholders' meeting at the Immune Suppression Syndrome (ISS) Clinic, a public outpatient HIV/AIDS facility in Mbarara, Uganda. Emenyonu was the project director for a research collaboration between Mbarara University of Science and Technology (MUST) in Uganda and two American institutions, the University of California, San Francisco (UCSF) and Massachusetts General Hospital (MGH). Since 2004 she had been responsible for transforming the clinic's paper-based medical record system, including 1,000 patient's antiretroviral therapy (ART) records, into an electronic medical record (EMR) system.

By 2010 nearly 10,000 patients were receiving ART at ISS Clinic, and the EMR system had become more sophisticated and costly to operate. As the UCSF representative, Emenyonu's role was to support efforts to generate ample high-quality data. She had to determine how to develop and maintain a strong, positive relationship with the clinic stakeholders, local clinicians, and other staff, many of whom viewed the EMR system as somewhat tangential to ISS Clinic's clinical responsibilities, and to determine how to finance the EMR with grant funding dwindling.

Overview of the Republic of Uganda

As of 2011, the Republic of Uganda was a landlocked country on the Equator in East Africa. It shared its northern border with Sudan, its western border with the Democratic Republic of Congo, its eastern border with Kenya, and its southern border with Rwanda, Tanzania, and the largest lake in Africa, Lake Victoria (see Exhibit 1 for map).

Uganda had two official languages, English and Swahili, and many other spoken languages.¹ There were multiple ethnic groups in Uganda; the largest were the Baganda, representing approximately 17% of the population. In 2008 the primary school education completion rate was 56%.¹ Adults age 25 and older reported an average of 4.7 years of education in 2010.² The agricultural and fishing industries were the largest employers in Uganda, providing roughly 80% of jobs.^{1,3} While international migration was limited,

Amy Madore, Julie Rosenberg, and Rebecca Weintraub prepared this case with assistance from Maria May, Jonathan Payne, and Joaquin Blaya for the purposes of classroom discussion rather than to illustrate either effective or ineffective health care delivery practice.

Cases in Global Health Delivery are produced by the Global Health Delivery Project at Harvard. Cases in Global Health Delivery are produced by the Global Health Delivery Project at Harvard. Case development support was provided in part by The Pershing Square Foundation. Publication was made possible free of charge thanks to Harvard Business Publishing. © 2012 The President and Fellows of Harvard College. This case is licensed Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported.

roughly 20% of the population had moved from one Ugandan district to another in 2005/2006 for employment and other income-related reasons (28%), civil insecurity (26%), and marriage and joining family (15%).⁴

Although fewer than 10% of Ugandans had access to electricity in 2011,⁵ the use of information technology (IT) resources was increasing. Uganda was one of the first Sub-Saharan African countries to have Internet access and e-mail services (starting in 1994). In 1999 there were about 12,000 people using the Internet, and by 2007, about 125,000. Uganda founded its Ministry of Information and Communications Technology in 2006 to expand the IT sector and align it with the country's strategic growth and development plans.⁶

| INDICATOR | | YEAR |
|--|------------------|------|
| UN Human Development Index ranking | 143 (out of 169) | 2010 |
| Population | 32.7 million | 2010 |
| Urban population (%) | 13 | 2009 |
| Drinking water coverage (%) | 68 | 2006 |
| Poverty rate | 52 | 2010 |
| (% living under USD 1.25 PPP ^b per day) | | |
| Gini index | 43 | 2010 |
| GDP per capita in PPP (2008 USD) | 1,251 | 2010 |
| GDP per capita (constant 2009 USD) | 490 | 2009 |
| Adult literacy (% ; total/female/ male) | 73/65/ 83 | 2010 |
| Corruption Perceptions Index (CPI) score | 2.5 | 2010 |

Basic Socioeconomic and Demographic Indicatorsa

Health in Uganda

In 2009 the adult mortality rate was 449 per 1,000 people. The top causes of death for all ages were HIV/AIDS (25%), malaria (11%), lower respiratory infections (11%), diarrheal disease (8%), and perinatal conditions (4%) at the time of the last WHO report.⁷ By 2009, malaria had surpassed HIV/AIDS to become the leading cause of morbidity and mortality.⁸

Health System

Upon independence, the Government of Uganda inherited a colonial health system centered on hospitals. During the political violence of the 1970s and 1980s, existing physical infrastructure decayed, and fragmented humanitarian aid was the primary source of health care. At the national level, Uganda's Ministry of Health (MOH) governed the public health system and was responsible for setting public and private health standards and mobilizing resources. It also advised health districts, coordinated health research, and monitored the performance of both public and private health care providers.⁹

^a This data was compiled from the following sources: United Nations (UN), World Bank, World Health Organization's Global Health Observatory Data Repository, and Transparency International. CPI scale ranges from 1 to 10, with 0 signifying "highly corrupt" and 10 signifying "clean."

^b Purchasing power parity.

Under the country's first strategic health plan during the mid-1990s, the MOH implemented a policy of decentralization. It gave greater regulatory and decision-making power to the provincial health authorities and established four levels of care: national referral hospitals, regional referral hospitals, general hospitals, and district and sub-district health centers. Nearly three-quarters of the population lived at least 5 kilometers from the nearest public or private health facility. Although the Government of Uganda abolished user fees in 2001, poor road infrastructure, health workforce shortages, medication and transportation costs, and drug stock-outs regularly constrained access to health services. 9, 10 Only slightly more than half (54%) of health care positions in the public sector were occupied. About 54% of health care providers worked in both the public and private sectors, and 22.5% worked only in the private sector.

The private sector—including nonprofit organizations, for-profit practices, and traditional healers—accounted for the majority of health care delivery in Uganda. Sixty percent of the population sought care from traditional healers (e.g., herbalists and spiritualists). Facility-based nonprofit institutions, primarily faith-based organizations, accounted for 41% of Uganda's hospitals.

Health System and Epidemiologic Indicators^c

| INDICATOR | | YEAR |
|--|----------|------|
| Average life expectancy at birth (total/female/male) | 52/57/48 | 2009 |
| Adult mortality rate (per 1,000) | 449 | 2009 |
| Maternal mortality ratio (per 100,000 live births) | 430 | 2009 |
| Under-five mortality rate (per 1,000 live births) | 128 | 2009 |
| Infant mortality rate (per 1,000 live births) | 79 | 2009 |
| Vaccination rates | | |
| (% of DTP3 coverage among one-year-olds) | 64 | 2009 |
| Undernourished (%) | 15 | 2006 |
| Adult (15-49 years) HIV prevalence (%) | 6.5 | 2009 |
| HIV antiretroviral therapy coverage (%) | 39 | 2009 |
| Tuberculosis prevalence (per 100,000) | 278 | 2009 |
| DOTS coverage (%) | 100 | 2006 |
| Malaria cases (per 1,000) | 40 | 2009 |
| Government expenditure on health as a % of total | | |
| government expenditure | 11.6 | 2009 |
| Government expenditure on health per capita | | |
| (PPP international dollars, USD) | 22, 8 | 2009 |
| Total health expenditure per capita | | |
| (PPP international dollars, USD) | 115, 43 | 2009 |
| Total number of physicians | 3,361 | 2005 |
| Physician density (per 10,000) | 1 | 2005 |
| Nursing and midwifery density (per 10,000) | 13 | 2005 |
| Number of hospital bedsd (per 10,000) | 4 | 2009 |

_

^c This data was compiled from the following sources: WHO, UN Children's Fund (UNICEF), UN Development Program (UNDP).

^d Hospital beds include inpatient and maternity but not cots and delivery beds (Source: WHO Global Health Observatory Data Repository).

In 2009 external donors contributed 40% of total health expenditure (USD 253 million) in Uganda. Out-of-pocket spending constituted 50% of health expenditures, and the Government of Uganda contributed the remainder.

In 1996 the MOH launched a national Health Management Information System (HMIS) to generate data that would inform operational decisions. Private and public health facilities were responsible for collecting data on standardized paper forms and sending them to the sub-district level, which relayed them to the district level. District-level administrators sent the forms to the central health data bank.¹¹ Underreporting was common, however, and only 68% of facilities submitted their reports to the MOH on time. Some health facilities started to use electronic databases such as Microsoft® Access to record and relay data; however, most did not have computer access, reliable electricity, and/or staff proficient in computer-based data entry. Despite efforts to prevent redundancies, the verticality of MOH programs, the participation of multiple Ugandan sectors (e.g., health and finance), and the involvement of international donors led to the rise of several monitoring and evaluation systems that increased the burden on the health workforce.⁹

HIV in Uganda

In 1998 the Government of Uganda introduced antiretrovirals (ARVs) through the Drug Access Initiative with support from the Joint United Nations Program on HIV/AIDS (UNAIDS), but access remained limited. In 2004 funding from the United States President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), allowed Uganda to offer free ARVs. By the end of 2009, 53% of HIV-infected people in need of ART were receiving it. There were 398 active accredited "ART service outlets" in the public and private sectors across 96 of Uganda's 97 districts, including all public hospitals, in March 2010. More than half (62%) were providing pediatric services as well. About 88% submitted quarterly reports on the services they provided for the 218,359 active ART clients they saw between January and March 2010 to the MOH. Approximately one-third of patients received ART at specialized AIDS clinics; the rest of patients went to general hospitals (25.4%), referral hospitals (19.1%), advanced health centers (14.8%), basic health centers (4.2%), and private clinics (3.4%).

In 2010 Uganda had a generalized HIV epidemic with an adult prevalence of 6.4%. The most common modes of transmission were sexual (76% of new HIV infections) and mother-to-child (22% of new HIV infections). Women, urban residents, and people living in post-conflict northern Uganda were disproportionately affected by HIV/AIDS. 15

Electronic Medical Records

Historically, health facilities recorded patients' medical histories, clinical, and demographic information on paper. In the 1960s and 1970s, there was a growing interest in the potential for information technology to drive innovation and improve the efficiency and quality of health care. Programmers in the US and other developed countries began to develop electronic medical records (EMRs). Proponents believed EMRs could enable faster, more reliable data storage and retrieval. EMR systems could display patient data, such as age or weight over time, with just a few clicks of the computer mouse and well-programmed queries. EMRs also regulated certain processes (e.g., legibility or level of detail recorded) and procedures that might

_

^e These data were the results of the 2004/2005 Uganda HIV&AIDS Sero-Behavioral Survey (UHSBS); as of 2010, these figures represented the most recent national HIV/AIDS prevalence data available.

have been more difficult to regulate through a paper-based system. As the Internet developed and became more accessible, several EMR systems incorporated web-based features such as search tools or e-mail.

Despite mounting excitement in developed countries about the potential of EMRs, in 2009 fewer than 2% of US hospitals had a comprehensive EMR system (i.e., integrated with all clinical units), and 7.6% had a basic system (i.e., present in at least one clinical unit). Adoption by smaller clinics and practices was even lower. Financial barriers and limited evidence that EMR systems were cost-effective were deterrents to EMR adoption. In fact, a poorly implemented EMR system might reduce efficiency and increase costs, facilitating unintended clinical errors or leading to dissatisfaction and conflict among personnel, for example.

EMRs in Developing Settings

As ART became more consistently available with the increase in international donor support in the early and mid-2000s, clinics' patient enrollment grew. By the end of 2009, the Global Fund and PEPFAR alone had financed ART for approximately 5 million people in more than 100 countries.^{19, 20} With ART, a patient could live 40 additional years in the developed world^{21, 22} or about 27 to 30 additional years in places such as Uganda.²³ As patients lived longer, compiling and monitoring patient information over time-including vitals, CD4 count, and viral load—using paper-based medical records became a greater challenge. Paper files overwhelmed administrative staff and clinicians, leading to patient registration delays and longer waiting times. It became harder to create progress reports for donors and other stakeholders, to gauge which patients were adherent, and to determine how many patients were lost to follow-up. Moreover, if anyone wanted to use clinic data for research, it was tedious and, in large-scale HIV treatment programs, nearly impossible to select participants systematically.²⁴

In offering ART, clinics also had to track inventory and forecast needs to prevent stock-outs. This required knowing the volume of patients enrolling, how many previously enrolled patients were still on first-line treatment, and how many needed to transition to second-line therapies. Given the information management challenges that came with ART, some program managers decided to switch to electronic information management systems, especially those with funding to do so or a research agenda.

In 2001 the Moi University School of Medicine in Eldoret, Kenya, partnered with the Regenstrief Institute, Inc., and Indiana University in Indianapolis, US, to create the first outpatient EMR system in Sub-Saharan Africa (see Exhibit 2 for examples of other EMR systems used in developing settings). Using Microsoft® Access, they developed the Mosoriot Medical Record System (MMRS) for use at the newly launched Academic Model Providing Access to Healthcare (AMPATH) project, a primary care clinic in a rural community of western Kenya. As AMPATH expanded to offer HIV/AIDS prevention and treatment in western Kenya, it needed an EMR with greater capacity, functionality, and flexibility than the MMRS. The Regenstrief Institute and Indiana University considered purchasing a system or altering an existing system, but they found the open source® EMRs either fell short of serving "both clinical and research needs—i.e., to collect non-ambiguous, coded data—or were not easily adaptable to [their] setting." They opted to design their own software, calling it AMPATH Medical Record Systems (AMRS). AMRS was modeled after the Regenstrief Institute's EMR system, which was being used to store more than 6 million patient records across 18 hospitals and 30 outpatient facilities in Indiana. AMRS became one of the largest EMR implementations for outpatient care in Sub-Saharan Africa.

^f AMPATH was founded jointly by Moi University School of Medicine and Moi Teaching and Referral Hospital, together with a consortium of North American universities led by Indiana University.

^g Software consists of a set of instructions (referred to as "source code") that guide the operations of a computer. Anyone can access open source code, whereas access to closed source code is restricted by the owner of the code.

OpenMRS

Partners in Health (PIH), a nongovernmental health care organization treating HIV/AIDS and TB since 1987, launched its EMR system to enable data collection and reporting in its Haiti- and Peru-based affiliated clinics in 2001. In 2004, PIH-EMR and AMRS creators met at an informatics conference and realized they were doing similar work; they shared a vision for developing an EMR system that could be customized for implementation in different contexts. Both had encountered challenges in adapting their EMR systems from HIV care to general care and from one country site to another. They decided to work together to build a stronger, more flexible, and more broadly accessible tool that other programs in resource–limited settings could use. Neither program had the resources to develop such a system singlehandedly.

At the same time, funders such as the World Health Organization (WHO) and the Rockefeller Foundation were receiving requests from programs in developing countries for financial support to develop or purchase customized EMR systems—particularly for HIV and TB, which were becoming increasingly complicated to treat as they became more chronic. Rather than give money to individual programs, funders believed they could expand their impact by seeding the development of one generic platform that many organizations could adopt. With funding from the Rockefeller Foundation, the WHO, and PEPFAR, the Regenstrief Institute and PIH joined forces with the South African Medical Research Council in 2004 to launch the Open Medical Record System, or OpenMRS®.

All of the OpenMRS source code was publicly and freely available, and there were no product or licensing fees associated with downloading the software. In principle, any user could download OpenMRS and immediately begin to establish users, create forms, and run reports. Operating OpenMRS required minimal programming expertise (though adapting the system to specific clinical settings and incorporating special functions that did not come with the basic software package, such as text message (SMS) alerts or requiring double entry, did require medical and coding knowledge; see **Exhibit 3** for more OpenMRS features).²⁸

Developers and implementers using OpenMRS in the field could communicate via OpenMRS group email lists (i.e., listservs), discuss questions and challenges in real time via an online forum called Internet Relay Chat (IRC), and access practical resources on the OpenMRS Wiki.h Community members discussed and advised each other on development and deployment issues, submitted new feature requests to the OpenMRS development team, documented software problems (i.e., bugs), learned about upcoming informatics conferences and meetings, and could access user and developer guides. By facilitating collaborative development and problem-solving through a virtual network, the OpenMRS team hoped it would enable sites to save time and resources by becoming more self-reliant and optimizing OpenMRS utilization.²⁹ An annual OpenMRS conference began in South Africa in 2005 with funding from the Canadian International Development Research Centre (IDRC).

In 2010 PIH, the South African Medical Research Council, Regenstrief Institute, and the Millennium Villages Project provided core funding support for OpenMRS. In addition, the IDRC, Rockefeller Foundation, and WHO contributed substantial grant-based funding. Other donors included the US Centers for Disease Control and Prevention (CDC); the National Institutes of Health (NIH) Fogarty International Center, Google; and other for-profit, nonprofit, and academic partners. By 2011 OpenMRS was being used for clinical and/or research applications in more than 25 countries, a majority of which were African, supporting over 1 million patient records worldwide.

_

^h A wiki is a type of type of website that allows users to contribute, revise, and remove content. The OpenMRS Wiki and mailing lists are public access and free to view and join: https://wiki.openmrs.org/display/docs/Home.

ISS Clinic at Mbarara Regional Hospital

History of ISS Clinic

In November 1998 American Dr. Larry Pepper, a physician working with the Baptist Mission in Uganda and teaching at Mbarara University Teaching Hospital—the teaching hospital for the Faculty of Medicine at Mbarara University of Science and Technology (MUST), founded the Immune Suppression Syndrome (ISS) Clinic to offer compassionate care to HIV-positive patients. The clinic was located in Mbarara, a small urban trading center in southwestern Uganda, in a small complex within Mbarara Hospital grounds.

In 2000 Dr. David Bangsberg, an American researcher at the University of California, San Francisco (UCSF), received an invitation to help MUST and Makerere University in Kampala develop a pilot study investigating treatment adherence and outcomes among AIDS patients living in severe poverty. Bangsberg was struck by what he saw: ARVs were available for purchase, but very few patients could afford to buy them. In response, Bangsberg established the Family Treatment Fund (FTF) in 2002 to provide ART for free to ISS Clinic patients who could not afford it and would likely die in the next 6–12 months without it. Bangsberg's work with FTF led him to shift his research from vulnerable populations in the US to southern Uganda's generalized epidemic.

Following a grand rounds presentation at MUST in 2003, Bangsberg met a young physician named Dr. Bosco (Mwebesa) Bwana (see **Exhibit 4** for profile), a clinician at ISS Clinic. Bwana had created a Microsoft® Excel spreadsheet containing demographic and clinical information from the paper files of ISS Clinic's first 500 patients. He asked Bangsberg how the spreadsheet could be improved and adapted to generate required ART reports for the Ministry of Health and to support research programs.

When the ISS clinic became a Global Fund and PEPFAR beneficiary in 2004 and 2005, respectively, it became the outpatient ART center of Mbarara Regional Hospital and began offering free treatment. In only a few years the clinic saw its patient enrollment jump dramatically. As the project director explained:

You have to understand that we went from having 1,000 patients receiving a little more than words of hope to 10,000 patients receiving comprehensive HIV care virtually overnight. The clinical staff went from Dr. Pepper, Dr. Bosco, and a counselor to a well-funded, multipartner effort in the same short span. It turned into a different entity once the PEPFAR funds were available; we had multiple partners, each contributing significant resources, and it became a little bit more difficult to manage, given the structural and political complexities.

ISS Clinic received PEPFAR funding as a sub-grantee through two Ugandan institutions: the Joint Clinical Research Centre (JCRC) and the Mulago–Mbarara Joint AIDS Program (MJAP) (see Exhibit 5 for organogram of organizations involved). Global Fund finances went through the Ministry of Finance, Planning, and Economic Development to the MOH, which delivered the finances to the clinic. The FTF shifted its focus to resolving emergency ARV stock–outs and treating patients on the waitlist for PEPFAR–funded treatment. In the midst of these financial transitions, UCSF and MUST officially launched a research partnership in 2004, and Bangsberg returned to California to fundraise for the project.

Service Delivery at ISS Clinic

ISS Clinic consisted of a two-story building—housing the registration office, waiting area, and patient consulting rooms on the first floor, and the data management offices and patient records department on the second floor—and a building housing the clinic director's and administrative offices, ART counseling offices,

ⁱ See http://familytreatmentfund.org for more on the Family Treatment Fund.

7

a laboratory, a conference room, and two pharmacies (one for ARVs and one for medications to treat opportunistic infections) built in 2007. The clinic director was a MOH employee and medical doctor, responsible for coordinating ISS Clinic's institutional stakeholders and overseeing its staff, including its doctors, a pediatrician, clinical officers, nurses, adherence counselors, data entry clerks, a data manager, a receptionist, peer educators, pharmacists, and lab technologists. Staff turnover was high; in one year, three medical officers left ISS Clinic for other health facilities.

On any given day, there were four or five clinicians and one pediatrician in the clinic. Though some clinicians were full-time employees, not every clinician was in clinic every day of the week. In addition to the clinic director, the MOH paid the pediatrician and one clinical officer. MUST paid Bwana, while MJAP, which paid significantly higher salaries, paid the other clinicians. Faculty members from the Department of Internal Medicine at MUST served as clinic advisers, spending one day a week for a few months at a time consulting with the full-time clinicians and seeing patients. In addition, the MUST postgraduate medical students spent part of their internship year in ISS Clinic. Occasionally, visiting clinician researchers from UCSF spent time there as well. None of the local physicians were trained specifically in HIV/AIDS. Clinicians completed five years of medical training and one internship year before becoming licensed medical doctors. As one physician explained, "We don't encourage sub-specialization because there isn't enough manpower. Dr. Bosco Bwana and others are not specialists in HIV per se, but they have a lot of experience."

Because the medical team at ISS Clinic changed frequently, it was not uncommon for patients to see a different clinician at each visit. Clinicians relied on medical records to prescribe care for the approximately 200 adult patients and 40 pediatric patients seen at the clinic each day (see **Exhibit 6** for a description of patient flow).

Information Collection and Management

Paper Records

Prior to 2004, ISS Clinic used a paper-based registry book, patient encounter forms, questionnaires, and blank sheets of paper to document patient information and clinicians' notes. At a patient's first visit, the clinic receptionist or a nurse started a new paper file and an initial encounter form and created an identification number for the patient. If the patient had been to the clinic before, the receptionist or a nurse collected the patient's paper file from the records room and started a return visit encounter form, writing the patient's name and the date at the top before taking the patient's vitals and recording them in the designated areas. There were also two or three pages of prompts or "checkpoints" designed to guide the clinicians and ensure they did not miss any details; for example, there were questions about the patient's ART regimen, adherence, and comorbidities (e.g., TB). The majority of questions were followed by checkboxes. There were some blank spaces to detail the chief complaint and treatment plan (see Exhibit 7a and 7b for patient encounter form).

The oldest encounter forms and notes were at the back of patients' charts, so to review any previous measurements (e.g., weight), treatment regimens, or test results, clinicians flipped through the file until they found it. Occasionally it was challenging to decipher other physicians' handwriting.

The ISS Clinic used the same clinical, paper-based records to compile reports for stakeholders. When a funder (e.g., the MOH) wanted to know how many patients the clinic was treating, the staff tallied patient records by hand. When a funder asked for information about specific outcomes, staff had to flip through the pages of each chart to review the patients' treatment regimens and outcomes over time.

With the establishment of the UCSF-MUST partnership in 2004, Pepper and Bwana wanted to develop a more efficient—ideally, electronic—patient registry. They hoped it would facilitate reporting. Bangsberg and UCSF colleague Dr. Jeffrey Martin began preparations to create an electronic database at ISS Clinic that would speed the process of aggregating and analyzing clinic data. They hoped it would also build research capacity at MUST and streamline patient care. Bangsberg and Martin had worked together for several years on HIV adherence research in San Francisco. They hoped that research in Uganda would help to improve interventions in resource-limited settings and prove to the international donor community that ART delivery was not only crucial but feasible in Sub-Saharan Africa.

Electronic Registry

Bangsberg and Martin secured a USD 1.7 million NIH grant to study treatment resistance, adherence, and survival at ISS Clinic for a year. Spending most of the year in California, Bangsberg hired Nneka Emenyonu to be the project director of the NIH-funded research collaboration between UCSF and MUST and to supervise the on–the–ground implementation of a new, computerized data collection and reporting system. Emenyonu had lived in West Africa until she was 19 years old and had both clinical research and public health experience (see **Exhibit 4** for profile). Emenyonu explained her role:

We had a clear mission to build capacity in the clinic because we were planning on working in the clinic ... They didn't specifically ask for us to help them develop an electronic medical record system. However, we needed it to realistically implement our research. There was no way we were going to recruit patients in a systematic fashion when the clinic didn't have an electronic method for keeping track of their patients.

Bangsberg asked Jay Jankowski, who had built datasets for his other research projects, to develop a Microsoft® Access database for ISS Clinic. Jankowski began building the database at UCSF with Bangsberg's guidance before flying to Uganda to visit ISS Clinic, install Access, and train Emenyonu's newly hired part-time data manager, Nicholas Musinguzi. Musinguzi had a bachelor's degree in statistics and computing from Makerere University and some knowledge of epidemiology and biostatistics. Jankowski worked with Bwana to determine what information he wanted to track while Emenyonu ensured that the electronic forms would also support potential research projects.

Emenyonu hired one full-time and one part-time data entry clerk with basic computer skills to enter the encounter form data into the electronic database and run reports. With limited research funding for human resources, Emenyonu initially used Bangsberg's UCSF discretionary funds to pay the salaries of the data manager (USD 500 per month) and clerks (USD 300 each month). She also hired file clerks (for less than USD 50 per month) to organize the patient file room and move paper files between the file room, registration desk, the data management office, and the patient consult rooms.

Emenyonu worked with the UCSF team and ISS clinicians, particularly Bwana, to adapt ISS Clinic's paper encounter forms so they would mimic the electronic forms of the Access database (see Exhibits 8a and 8b for Access forms). Several of the clinicians felt overwhelmed by the new forms, which were longer and more prescriptive than the previous ones. It was not uncommon for physicians to leave areas of the patient encounter forms blank; many viewed the EMR system as a tool to support the UCSF research agenda.

When JCRC and MJAP began to finance ISS Clinic with PEPFAR funding in 2005, Bangsberg and Emenyonu were able to redirect some of their funding to buy additional computers and filing cabinets. They came to rely less on Bangsberg's discretionary UCSF research budget. Bangsberg and Emenyonu used a USD 72,000 grant from the Rockefeller Foundation to cover the cost of running and staffing the database. She also tried to include resources for database operational costs in UCSF's applications for smaller research grants.

By 2005 there were several thousand EMRs in the database. System performance slowed, and the limited number of user accounts Access could accommodate became problematic. Emenyonu and her UCSF colleagues worried that Access's storage capacity and functionality would not keep pace with the clinic's rising patient load.

A New System

Later that year, Bangsberg received a phone call from Dr. William Tierney, the Director of Research and Informatics at the AMPATH project in Eldoret, Kenya. Tierney believed that "health care was an information business" and had called to encourage Bangsberg to apply to a new NIH–funded grant opportunity through the International Epidemiologic Databases to Evaluate AIDS (IeDEA). IeDEA aimed to establish regional consortia worldwide to which individual cohorts related to HIV disease would contribute their data. The East Africa Regional IeDEA Consortium included Uganda, Kenya, and Tanzania. This pooled data would be more representative than any single center's data and have enough patients to allow for the study of rarer clinical occurrences. Each grantee would receive five years of funding.

The WHO and the Rockefeller Foundation were providing AMPATH with financial support for OpenMRS, and they were interested in finding other sites to test the software. They selected three pilot implementation sites in concert with the Ugandan Ministry of Health: ISS Clinic at Mbarara Regional Referral Hospital; the HIV clinic at Masaka Regional Referral Hospital, supported jointly by Uganda CARES; and the HIV clinic at Mbale Regional Referral Hospital.

Having little technical background in electronic medical record systems, Bangsberg and Martin acknowledged, "It was not a highly informed decision to use OpenMRS. We wanted to be a research group, and there was some money there to use to begin with OpenMRS ... When you have a limited budget and find an opportunity, you pretty much take it." Martin also noted, "Microsoft® Access did not have a fixed package to be used for medical record systems, so anything that was done with it had to be built from scratch ... People have been working on EMRs for a while, and the team in Eldoret had sizable experience with OpenMRS" (see Exhibit 2 for more on other EMR systems).

Transition

In preparation for implementation, Nicholas Musinguzi became a full-time data manager. Bangsberg secured a USD 40,000 grant from the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration to hire an additional full-time data manager to oversee the UCSF-MUST field site, a small university building located 200 meters from the clinic facilities used for interviewing and other research-related activities. Bangsberg and Emenyonu also used the grant to hire more data entry clerks ("data entry specialists"), increasing the number from two to eight, file clerks ("records assistants"), a receptionist nurse, and a patient tracker (see Exhibit 9 for the clinic's ART-LINC budget).

The Faculty for Computing and Information Technology at Makerere University received funding from the WHO to assign three of its employees to support OpenMRS implementation. ISS Clinic was the first site to initiate the implementation process in January 2007. The Makerere team traveled four hours to Mbarara to teach Musinguzi to install OpenMRS software, program the electronic forms, develop standard reports the data entry clerks could run, and update the electronic forms and build ad hoc reports in the event that the clinic wanted to capture and report on different indicators.

-

^j The ART-LINC Collaboration was a network of HIV treatment programs and cohorts in developing countries financed by the NIH and France's National AIDS Research Agency.

Emenyonu allocated a USD 80,000 grant from the WHO to purchase computer and office equipment. Bangsberg also received continued funding for the NIH adherence, resistance, and survival study through June 2008 (see Exhibit 10 for detailed WHO budget).

All of the clinic's computers were connected via a hardwired local area network (LAN), meaning that they could share and synchronize data without an Internet connection. Internet access was not essential to operating the OpenMRS database, although it was necessary to access the OpenMRS online community and e-mail the UCSF team. The only point of regular Internet access at ISS Clinic was in the director's office.

The first step to making OpenMRS operational was to design the electronic data input forms. Designing the electronic forms occurred in tandem with the revision of ISS Clinic's paper encounter forms. The UCSF team sent Musinguzi and Bwana to San Francisco and Eldoret to learn from the UCSF research team and AMPATH how to design the patient encounter forms and translate them into electronic versions in OpenMRS. "If one has a form that promotes nonreproducible completion by the clinicians, you are doomed from the get-go. Create systems that generate clear and unambiguous responses and then have a process in place that attempts to find inconsistency or 'missingness' shortly after the data is collected," Martin explained.

When Bwana and Musinguzi returned to Mbarara, Emenyonu solicited the other clinicians' feedback on the paper encounter forms. Emenyonu explained to the clinicians why OpenMRS was a useful clinical tool as well as an instrument for research. She highlighted a newly developed OpenMRS feature—the patient summary module—that enabled users to print one-page clinical summaries of patient information. It would include past lab results, recent CD4 counts, viral load, vital signs from the previous four visits, ARV history and regimen, other concomitant medications, and any side effects experienced. The module would also use Clinical Decision Support Systems (CDSS) functionality to display care-related suggestions and reminders (e.g., "Repeat CD4 count!") for clinicians. Plans were to integrate the patient summary module shortly after OpenMRS was implemented. Emenyonu made final revisions to the paper encounter forms and conducted group meetings with the clinicians to instruct them how to complete the forms (see Exhibits 11a and 11b).

Despite their involvement in this process, after OpenMRS was implemented, clinicians were generally unaware of the transition from one electronic system to another. One clinician explained, "We never changed. The source for clinicians was still paper. The clinicians themselves still don't enter anything in the computer. The only thing we see from the EMR system is the patients' last results. The clinician does not have database access or enter anything into it." Some of the clinicians who were part of the UCSF-MUST research team, such as Bwana, used the database to conduct research, but the data management team generated the reports, not the clinicians.

JCRC- and MJAP-affiliated clinicians were frustrated that they had to use the UCSF team's encounter forms. The forms were more detailed and comprehensive than the standardized "blue" forms the MOH had developed and disseminated to public HIV clinics throughout the country. Collecting data that was not solicited by the MOH through its data collection tool went beyond their normal clinical duties, clinicians protested, and they therefore should be paid more to do so. Emenyonu hoped that she could convince them otherwise when they began to see and appreciate the clinical utility of OpenMRS.

Emenyonu and the UCSF team decided to merge everything in Access, including records of patient visits since 1998, into OpenMRS. Musinguzi's initial attempt to do this electronically was unsuccessful, however, so the two databases existed simultaneously for a while before being merged. Emenyonu explained, "It was more technically complicated than we envisioned. We were just learning as we went along."

Not all of the ISS Clinic databases transitioned to OpenMRS. The laboratory and pharmacies operated their own Access databases independently from UCSF. Pharmacy data and lab results were incorporated into the UCSF database manually; the lab technicians and pharmacists printed reports from their computers and sent them to the data management room, where data entry clerks added the data to patient records (see **Exhibit 12** for a screenshot of the OpenMRS data entry interface).

OpenMRS at ISS Clinic

After launching OpenMRS, Emenyonu met regularly with the clinic director and stakeholders from JCRC, MJAP, MUST, and Mbarara Hospital about OpenMRS and how it was working. ISS Clinic had access to a midlevel information technology professional at MUST who helped with computer and IT issues. For problems that required the purchase of new software or hardware, Emenyonu relied on Bangsberg's discretionary funds or small research grants that included minimal support for miscellaneous database needs. For example, when the clinic's antivirus software license expired and a virus infiltrated the computer system, Bangsberg's discretionary funding helped replace the server and buy new antivirus licenses for all of the clinic's computers. Once the IeDEA grant came through, it supported most of the database work and eventually provided all the database funding.

Because the OpenMRS software was only a few years old, bugs and errors occurred frequently. When Musinguzi encountered a bug that he could not fix on his own, he initially reached out to technologists at Makerere University. He soon discovered that they did not have enough time or knowledge of OpenMRS to help him. He turned to the global OpenMRS online community, where he received practical advice and solutions within 24 hours. "OpenMRS has been a lot harder than I thought it would be," Martin acknowledged. "Technically, it doesn't follow more conventional database structures, so not just anyone can work with it or understand it. That's been unfortunate." As Musinguzi interacted more with the OpenMRS community, he became increasingly familiar with how to solve common technical problems.

One challenge that Musinguzi struggled to resolve despite input from the OpenMRS community was incorporating the patient summary module into the database. With these technical complications and the manual merge of Access and OpenMRS data, patient summaries did not become operational for approximately 18 months. Emenyonu reflected:

We had a situation where the clinicians really didn't see the clinical relevance of the data they were collecting, and they didn't see the clinical relevance of the system because its implementation took so long. I think that was a major mistake in implementing the system ... Clinicians participated in developing the forms, but we also should have made sure that the clinical components were up and running sooner than the research components.

In 2008 Bangsberg transitioned from UCSF to Massachusetts General Hospital (MGH) in Boston, bringing an additional group of stakeholders to the ISS Clinic. While at UCSF, Bangsberg had limited discretionary funds, at MGH he would have access to a larger community of donors. Martin remained in California and asked his research fellow, Dr. Elvin Geng, to help direct the UCSF component of the work.

Emenyonu struggled to convince JCRC, MJAP, the MOH, MUST, and Mbarara Hospital that the EMR system was essential to ISS Clinic's success. Emenyonu encouraged them to include database operational costs in their grant proposals, and she regularly invited MUST professors and students to use OpenMRS for their research.

By August 2008, the clinic had enrolled over 15,000 HIV-positive patients.³¹

Data Uses

The patient summary module became operational at the beginning of 2008 (see **Exhibit 13** for patient summary example). The receptionist was given a computer and a printer so that she could print a summary sheet when each patient registered. She placed the summary sheet on top of the patient's paper file after the file clerk retrieved from the records room.

Bwana, Emenyonu, Musinguzi, and others, led by an author from the Regenstrief Institute, published a study investigating the impact that patient summaries had on efficiency and "quality of care" at ISS Clinic. They found that clinical summaries shortened the amount of time it took clinicians to review patient data, enabling clinicians to spend more time with the patient, and shortened patient wait times by more than 30 minutes (see **Exhibits 14a** and **14b** for results of the time studies).³¹ Patient summaries also decreased the incidence of data errors by prompting face-to-face interaction between the data management team and clinical staff. If clinicians had a question about a value on the patient summary sheet, they could inquire with the data management team or send a nurse to do so. Similarly, if the data management team had a question (e.g., if the CD4 count was out of range or the drug dosage was incorrect—both of which OpenMRS automatically noted), they would walk downstairs to the patient consult rooms and inquire with the clinician. Clinicans were generally satisfied with the data summary sheets (see **Exhibits 15a** and **15b** for results of clinician satisfaction survey).³¹ Clinicians could also ask the data management team for data not captured on the patient summary or to run a particular query/report.

OpenMRS enabled ISS Clinic to inform staffing, procurement, and other administrative decisions by analyzing trends in patient visits over the course of a week or month. When leaders realized that Wednesdays had the lowest patient volume, they decided to close ISS Clinic on Wednesdays so staff could meet and focus on administrative work. Eventually, the clinic started to use the appointment scheduling feature of OpenMRS, which gave clinicians a sense of how many and which patients were likely to attend clinic on any given day. "The volume of what goes on at that clinic is difficult to get a handle on without an EMR," Geng affirmed.

The data management team produced stakeholder reports using the EMR system with relative ease, including biannual reports to the IeDEA Consortium, quarterly reports for the MOH, monthly reports for clinic stakeholders, weekly internal reports, and ad hoc reports according to needs.

OpenMRS was "indispensable" to research at ISS Clinic, according to Bangsberg and his team. "There would be no research or operations research or internal reporting without an EMR," Geng noted. Bangsberg and other senior researchers spent a portion of their in-country visits training and advising junior Ugandan investigators. The primary and recurring research focus was patient loss to follow-up. Geng described its value:

Patient retention and retention to care is a key aspect of care. People misinterpret clinic retention as patient retention, but you have to understand retention within the larger system of care. If you think about how care was rolled out—start at large hospitals and gradually care has been decentralized to smaller clinics—the whole point of decentralization is that patients who started at tertiary care centers end up receiving care at small delivery sites, but no one has accounting of that patient movement.

The UCSF team used the database as a launching point for the research. Martin explained: "It would have been impossible to do good research just by studying the people who don't disappear. The database was instrumental in identifying how many people are lost and who is lost. With the paper-based systems, you wouldn't know that—you couldn't quantify or know who is lost." The database allowed researchers to search for patients who failed to return to their appointments and generate a random list of them. The clinic hired an outreach director, bought him a motorcycle, and trained him to track as many of those patients as possible each week and bring them back to the clinic.

The UCSF/MGH team also turned to the database when a *New York Times* article³² revealed that PEPFAR-recipient clinics in Uganda were turning away or wait-listing HIV-positive patients. They used OpenMRS to look for ART-eligible patients and patients starting ART between April 1, 2009, and May 14, 2010, and discovered that there had been a two-month gap in PEPFAR-funded treatment in May 2009 and that no new patients had been enrolled in PEPFAR treatment slots since October 2009. The MOH, with Global Fund support, and FTF were bridging this gap by enrolling new patients on treatment; by May 2010, FTF was sponsoring almost 90% of ART initiations (100 people per month) at ISS Clinic, "... and we didn't even know it. It was a good thing we checked," Bangsberg recalled.

Geng described the EMR system's role in identifying the ARV shortage: "When there were limited ARVs, we documented it at the clinic and evaluated how this affected how long it took people to start therapy, and we brought in additional private funding to make up the gaps so that people didn't wait for long periods to receive clinical care." Unlike many of the MOH clinics, ISS Clinic had a relatively steady supply of ARVs, insured in large part by the multiplicity of stakeholders. According to one researcher, ISS Clinic had not experienced a true stock-out in several years. The research team, including Bwana and the ISS Clinic director, published its study in an online open-access journal, *PLoS ONE*.³³

If researchers wanted to investigate a variable not captured in the patient encounter forms (e.g., alcohol consumption, fertility desire), they used OpenMRS to screen and recruit study participants. They then created a separate questionnaire and database—typically using Access—to collect the information they needed. Most of the UCSF/MGH team's research required the creation of separate questionnaires and standalone electronic databases. For example, Bangsberg designed a study to assess the impact of transportation costs on adherence and retention. He used OpenMRS to identify eligible patients and created a paper-based questionnaire and an Access database to record patient information. The study showed that transportation costs were a reason patients cited for missing ARV doses and clinic appointments.³⁴ Bangsberg and the UCSF/MGH team then applied for funding to help ISS Clinic's poorest patients generate income (e.g., building chicken coops, purchasing chickens to raise, and selling eggs) and study the effect of income generation on adherence using a new dataset.

Blue Forms

At the beginning of 2010, the MOH notified ISS Clinic that it would no longer permit the clinic to use its own patient encounter forms. Instead, all public HIV/AIDS clinics in Uganda had to use the national "blue forms" (see Exhibits 16a and 16b for examples of forms). The UCSF/MGH research team amended its encounter forms to include the information in the MOH blue form and requested permission to use the modified form in lieu of the blue forms, explaining the need to collect additional data for research, but the MOH declined.

The blue form was shorter. It removed blank text boxes for clinicians' notes, replacing several of them with pre-formulated responses and corresponding checkboxes. The blue form's ARV regimen section used small text boxes instead of a checklist of medications and dosages, thereby prompting clinicians to write out their own abbreviations or name of the prescribed medications and dosages. Most of the data entry clerks did not have clinical knowledge, limiting the accuracy of their interpretations. According to one UCSF faculty researcher, "You went from banker's accuracy to free-form."

Emenyonu saw the blue forms as a small but potentially terminal step back for the EMR system.

ISS Clinic in 2010

Bangsberg and Emenyonu helped establish a grants and contracts office at Mbarara University to streamline the process of spending NIH grants and other research funding in Uganda. The office began receiving 8% overhead for HIV grants and up to 15% for other grants, gaining administrative capacity.

Stakeholders continued to view OpenMRS as the American universities' financial and administrative responsibility, however. Emenyonu explained:

There's still this concern on the part of the Ugandan clinicians that the data really belong to UCSF. The clinicians think, "Yes, it helps us in the clinic, but it's primarily Dr. Bangsberg's system ..." They're gradually beginning to accept it, but I think the underlying concerns about access, ownership, and perhaps even compensation sometimes, prohibit them from seeing the true value of an EMR system as a clinical tool. This concern is compounded by the fact that the US investigators are the first to publish papers using data from the ISS Clinic database. There has only been one publication from a Ugandan using data from the clinic database, and that person was not even a member of the clinic at the time; he was a member of our research team.

In 2010 there was a gap in IeDEA funds, and Emenyonu could not pay the data entry clerks' salaries for several months. She and the ISS Clinic director asked the MOH to help bridge the salary gap, but it declined. Emenyonu recalled a conversation with one of the hospital administrators: "But this is your program, so you figure out how to fund it.' I said, 'But it's part of the clinic,' and they said, 'Well, we didn't ask for it; it's your problem, so figure it out."

ISS Clinic was 1 of 66 ARV delivery sites in western Uganda. Since 1998, the clinic had seen nearly 21,000 patients, of whom almost 10,000 had been enrolled on ART. At the end of 2010, there were approximately 8,500 active^k adult patients and 1,000 active pediatric patients. Research from the clinic had contributed to more than 20 peer-reviewed articles (see **Exhibit 17a** for abbreviated list of articles and **17b** for select abstracts).

Three years after its debut at ISS Clinic, the OpenMRS database still lacked a long-term funding source. The IeDEA grant was drawing to a close, and while there would be an opportunity to apply for another five—year grant, the consortium was reducing its funding for the operational costs of running electronic databases. Emenyonu and the UCSF/MGH team would have to find additional funding, knowing they could only stretch the MGH donors' discretionary dollars so far. With her pending departure as project coordinator in the fall of 2010, Emenyonu worried that they had not secured the finances for the database and data collection:

I'm not sure it has completely registered that if the clinic database is discontinued, then a large part of the clinic's organization and planning will likely cease to exist. Could the ISS Clinic do with a less complicated, less sophisticated system? Maybe. Maybe the MOH system would be sufficient, but it would mean going back to the drawing board, and that would really set the clinic back ... The clinic database has raised the visibility of the institution. It has raised the quality of patient care, and the flow of patients throughout the day has vastly improved. But I imagine it is hard for the average clinician who sees patients on a day—to—day basis to immediately see the value.

What more could she do to convince the clinicians and stakeholders of the EMR system's value? How would they continue to sustain OpenMRS, and what would be the impact of shutting down the EMR system?

^k A patient was considered active if he or she had been seen at the clinic within the past six months.

Exhibit 1 Map of Uganda



 $Source: US\ Central\ Intelligence\ Agency,\ available\ at: https://www.cia.gov/library/publications/the-world-factbook/maps/maptemplate_ug.html.$

Examples of EMR Systems in Developing Settings Exhibit 2

| System | Launch | Developers | Implementation | Software | Implementation | Notable |
|--------------------------------------|-----------|--|---|--------------------|--|---|
| Open Medical Record System (OpenMRS) | Year 2004 | Partners in Health and Regenstrief Institute | Sites 25+ countries; national implementation by Rwandan Ministry of Health | Open source | Process Free software download, trained implementation team required, free online support community | Flexible platform, global support community |
| IQ Care System | 2004 | Constella Futures Group, Catholic Relief Services, and Futures Group (AIDS Relief) | Kenya ¹ , Uganda, Nigeria, Tanzania ^m | Open source | Free software download, custom options available, train the trainer program available | Used to administer PMTCT, antiretroviral therapy |
| Smart Care | 2005 | Zambia Ministry of Health, US Centers for Disease Control | National implementation in Zambia, including CIDRZ ⁿ ; Ethiopia, and South Africa | Not open source | Data unclear | Works with paper-based systems, durable design and limited Internet touch-screen option for easy learning |
| Care Ware | 2000 | US Department of Health and Human Services and PEPFAR; jPROG-developed the software | United States, Nigeria, Uganda, and Vietnam | Freeware | Free software download, free technical support, limited adaptability | Originally designed for HIV prevention and treatment |
| Baobab | 2001 | Baobab Health Trust | Malawi | Open source | Offers a suite of services, such as: open source software and low-cost hardware and operational support | Touch screen available for easy use, hardware designed for harsh environments, Malawi-based |
| OpenEMR | 2005 | Open Source Medical Software | United States, Puerto Rico, Australia, Sweden, Holland, Israel, India, Malaysia, Nepal, and Kenya | Open source | Free software download, options for customization, free online support, commercial support and licensing available | Multi language support, large online open source support community |
| OpenVistA | 2002 | US Veterans Health Administration | All VHA sites: 163 hospitals, over 800 clinics and 135 nursing homes; also used at sites in Mexico (over 100 hospitals), and 11 other countries around the world | Open source | Support license typically required for hospitals and larger clinics, commercial set-up available | Synchronization with multiple locations, management performance tools |

¹ This is one example of an EMR system in Kenya; there are several others, including Care 2000, Aphia II Coast, EDMS, C-PAD (I-CAP).

^m IQ Care is in operation at 81 hospital sites throughout these four countries.

ⁿ Largest medical record system in Africa in terms of patient volume.

| System Name | Launch Year | Developers | Implementation Sites | Software | Implementation Process | Notable Features |
|--|----------------|---|--|----------------|--|--|
| Community Health Tracking System (CHITS) | 2004 | UP Manila- National Telehealth with support from the Canadian International Development Research Center | Philippines | Open source | Free software download, training and certification through the UP Manila National Telehealth Center | Rapid access to patient data, Internet connection not necessary |
| Hospital OS | 2003 | Thailand Research Fund, Thai National Health Foundation, Thai Medical Informatics Association, Software Industry Promotion Agency (Thailand) | 75 hospitals throughout Thailand | Open source | Free software download, online support community, requires IT specialists to set up and run | Designed for rural Thai hospitals with limited IT budgets |
| Health Information Systems Program (HISP-SA) | 2001 | Government of South Africa, Norwegian Agency for Development Cooperation, USAID | South Africa, Kenya, Rwanda, Ghana, Lesotho, Zimbabwe, Mozambique, Sierra Leone, Uganda, Tanzania, and Latin America | Open source | Collaborative development for South Africa, implementation across African continent and Southeast Asia | South Africa- based; language options for Portuguese, Swahili, Spanish, Telugu, Russian, Mongolian, and Chinese |
| SIGA Saúde | 2004 | Centro de Estudos em Informática em Saúde [Center of Health Information Studies], Prefectura da ciadade de São Paulo [Prefecture of the City of São | Brazil: Cities of São Paulo, Camaçari, and Campinhas; other sites in the State of São Paulo | Open source | Developed for the city of São Paulo, costs for software development and hardware | Utilized by every public health care facility in the City of São Paulo |

Source: Compiled by case writers using publicly available sources.

Exhibit 3 Basic OpenMRS Features

| Feature | Description |
|---------------------------------------|---|
| Central concept | Definitions of all data (both questions and answers) are defined in a |
| dictionary | centralized dictionary, allowing for robust, coded data |
| Security | User authentication |
| Privilege-based access | User roles and permission system |
| Patient repository | Creation and maintenance of patient data, including demographics, |
| Multiple identifiers per patient | clinical observations, and encounter data, etc. A single patient may have multiple medical record numbers |
| Data entry | With the FormEntry module, clients with InfoPath (included in Microsoft® Office 2003 and later) can design and enter data using flexible, electronic forms. With the HTML FormEntry module, forms can be created with customized HTML and run directly within the web application |
| Data export | Data can be exported into a spreadsheet format for use in other tools (Excel, Access, etc.) |
| Standards support | HL7 engine for data import |
| Modular architecture | An OpenMRS Module can extend and add any type of functionality to the existing API and web app |
| Patient workflows | An embedded patient workflow service allows a patient to be put into programs (studies, treatment programs, etc.) and tracked through various states |
| Cohort management | The cohort builder allows users to create groups of patients for data exports, reporting, etc. |
| Relationships | Relationships between any two people (patients, relatives, caretakers, etc.) |
| Patient merging | Merging duplicate patients |
| Localization/ internationalization | Multiple language support and the possibility to extend to other languages with full UTF-8 support |
| Support for complex data | Radiology images, sound files, etc. can be stored as "complex" observations |
| Reporting tools | Flexible reporting tools |
| Person attributes | The attributes of a person can be extended to meet local needs |

Source: OpenMRS, $\underline{\text{http://openmrs.org/about/.}}$

Exhibit 4 Profile of Ugandan-Based Research Team Members

Dr. Bosco (Mwebesa) Bwana, Clinician, ISS Clinic

Bwana grew up in a small village near Mbarara. While still a teenager, his parents passed away from HIV. Bwana opted to pursue a career in medicine while caring for his six younger brothers and sisters. Bwana finished his five-year medical training and one-year internship at the ISS Clinic in 2002. He continued to volunteer at the ISS clinic until offered a medical officer position. Bwana was the first full-time clinician and persuaded the clinic to offer services Monday through Friday.

Nneka Emenyonu, Project Director, UCSF Epidemiology and Prevention Interventions Center

Nneka Emenyonu worked as the Project Director of the MUST-UCSF Research Collaboration in Mbarara, Uganda, though 2010. Emenyonu was born in Boulder, Colorado, and raised in Nigeria. She returned to the United States to attend Oberlin College in Ohio, where she completed a Bachelors of Arts in Biology. Emenyonu then attended the Johns Hopkins University Bloomberg School of Public Health in Maryland, where she received a Master of Public Health degree She coordinated breast cancer clinical trials at UCSF prior to joining the Epidemiology and Prevention Interventions Center. Emenyonu then instituted and built the MUST-UCSF Research Collaboration to expand capacity and learning so that African public health issues could be addressed primarily through African health professionals. She pursued a doctorate in public health, focusing on health policy and management, at the University of North Carolina Gillings School of Global Public Health.

Sources: Compiled by case writers and adapted from the UNC Executive DrPH in Public Health Leadership Class of 2010, available at:

http://www.sph.unc.edu/images/stories/academic_programs/hpaa/documents/drph_bio10.pdf.

Exhibit 5 ISS Clinic Collaborators and Their Roles, 2009

DEPT OF INTERNAL MEDICINE

- 1. Supervisory role
- 2. Specialist clinical staff

CANADA-AFRICA PREVENTION TRIALS (CAPT) NETWORK

1. Conduct clinical research trials

MINISTRY OF HEALTH (MOH)

- Employs staff (2 doctors, 1 clinical officer, 2 nurses, and 1 pharmacy technician)
- 2. Provides ART for 2500
- 3. Provides some drugs for opportunistic infections

WORDS OF HOPE

- Conducts home visits for spiritual care and adherence counseling
- Supplies food, assists clients in certain farming projects, provides mosquito nets to some

MULAGO-MBARARA JOINT AIDS PROGRAM (MJAP)

- 1. Offers RCT (provider-initiated HIV counseling and testing)
- 2. Provides ART to some patients (1,800)
- Provides most drugs for opportunistic infections and other medical conditions at ISS and medical ward
- 4. Supplies basic care kits supply (mosquito nets, condoms, water vessels, water guards)
- 5. Employs staff (4 doctors, 4 counselors, 2 lab staff, 6 nurses, 3 pharm techs, 3 data team)
- 6. Supports laboratory services (pays for CD4, lab tests for 4000 MOH, 2000 MJAP patients)
- 7. Provides equipment (e.g., computers, their accessories, and servicing) and furnishing (e.g., chairs, tables, etc.)
- 8. Provides data support

MUST-UCSF/MGH/HARVARD COLLABORATION

ISS CLINIC

- 1. Conducts research
- 2. Trains doctors and trains research assistants in research methods
- 3. Supports FTF: provides ART, counseling, and laboratory services to some ISS clinic clients
- 4. Employs FTF coordinator, nurse, receptionist, supports some volunteers
- 5. Follows up with patients who are lost from clinic
- 6. Supports infrastructure development; ensures ISS Clinic's data base is fully functional

JOINT CLINICAL RESEARCH CENTRE (JCRC)/TREAT PROGRAM

- 1. Infrastructure (offered to the ISS clinic), the new building and some furnishings
- 2. Employs staff (doctors, lab technologist[s], adherence officers, counselors, nurses)
- 3. Offers laboratory tests to its clients (forthcoming)
- 4. Offers ART to: adults (1,400) and children (approx 500)
- Supports training—facilitates staff attending training in HIV/ART courses, research courses, MPH
- Provides IT services (computers, printers, Internet connection to some offices)
- 7. Provides patient education and entertainment (through TV set/deck/VCR)
- 8. Provides a few drugs for opportunistic infections

IeDEA (International Epidemiologic Database to Evaluate AIDS)

1. Supports the EMR system data team

Source: Adapted from ISS Clinic materials.

Exhibit 6 Patient Flow at ISS Clinic

Patients typically arrived at ISS Clinic by way of referral from Mbarara Hospital, where both inpatients and outpatients received provider-initiated HIV testing on the hospital wards. The Mulago-Mbarara Joint AIDS Program (MJAP) provided this service by paying specific nurses to look for patients who had not already been tested. If a patient tested positive for HIV, the hospital referred him or her to ISS Clinic for additional counseling and treatment. Patients who enrolled at ISS Clinic but had not been sent by Mbarara Hospital typically came via referral from other facilities in the region or from another HIV clinic due to a move or other personal reasons.

When patients arrived at ISS Clinic, they registered with the receptionist in the registration office and then joined other patients in the waiting room. Peer educators and usually at least one nurse led discussions about health-related topics, such as nutrition, while patients waited to be called into the triage room. In the triage room, a team of three nurses measured patients' vitals (e.g., blood pressure, temperature, and weight), took blood samples, and recorded patient responses to questions regarding family planning, pregnancy, and the HIV status of their partner(s). Peer educators worked alongside the nurses to counsel or educate patients on health issues that had not been discussed in the waiting room. As they triaged patients, the nurses organized patients into groups based on the number of clinicians working that day. The triage process typically lasted for about one hour; once 20–30 patients had been triaged, the nurses moved them from the congested room and assigned groups of 8–10 patients to different consulting rooms where they sat on benches outside the office doors until the clinician or medical officer called each patient by name. The clinicians' offices were connected by doors so that clinicians could move between them.

Clinicians typically spent between 2 and 10 minutes with each patient. Patients who were relatively healthy and/or had been attending the clinic for several months and only needed a prescription refill might spend three or four minutes with the doctor, while a new or very sick patient might take up to 20–30 minutes. At the end of the visit, the clinician scheduled a follow-up appointment with the patient and advised him or her where to go next. If the clinician had prescribed ARVs and/or medication for an opportunistic infection, the patient took his or her prescription(s) to the ARV and/or OI pharmacy and picked up the medication. If the patient required further testing, the clinician would send him or her to the laboratory with a prescription for the necessary test(s). The clinician referred noncompliant patients to an adherence counselor. Before the patient left the clinician's office, he or she received a summary sheet showing the date of his or her next appointment and basic information about his or her health (e.g., CD4 count and weight).

Source: Compiled by case writers from informant interviews.

Exhibit 7a ISS Clinic Patient Encounter Form, 1998–2005, page 1 of 2

| | | 2 M ' 2 R 2 B 3 B 3 M |
|--------------------------------|--------------------|--|
| | Mbarara University | Teaching Hospital |
| AIDS Clinic Form | | |
| , | | Outpatient #: |
| Date of Registration (/ / / | | |
| Diarrhea > 1 month | Yes No | and the same of th |
| Fever > 1 month | | Address: Sex: M[] F[] Age: |
| Weight loss > 10% | | Sex: M[] F[] Age: |
| Cough > 1 month | | |
| Oral thrush | | Occupation: |
| Skin rash | | Tribe: |
| Herpes zoster | | Marital Status: Single [] |
| |) 1 1 1 | Married (1) |
| Right [] Left [] | , | (2) [] |
| Location: C Nerve | 1 | (3) [] |
| Cervical | 1 | (>3) [] |
| Thoracic | i | Divorced [] |
| Lumbar | i l | Widowed [] |
| Sacral | i l | Separated [] |
| Lymphadenopathy | | Children: |
| Cervical | | |
| | i | 5 : St. 1.1 |
| Herpes simplex | . [][-] | Si Children. |
| Ammenorrhea | | |
| Kaposi Sarcoma | | Date of onset of first symptoms (/ / /) |
| Location: | | Blood Transfusion [] YesNO |
| Silky hair | | |
| Hyperpimentation | | date: (/ /) |
| Paresthesias | | <u>Laboratory:</u> (+) (-) |
| Peripheral neuropathy | | ELISA#1 () 20074 |
| AIDS related Dementia | | ELISA#2 () () |
| Cranial Nerve abnormality | [] [/] | |
| Anemia | [][] | Initial clinical suspicion |
| Skin Sepsis | | HIV related illness |
| Pyomyositis | [] [] | |
| Viral warts | [][] | |
| |) [][/] | |
| Spleenomegaly (grade: |) [][] | Non-HIV illness |
| Alopecia | [][/] | |
| Lower ext. edema | [] [/] | |
| Cryptococcal meningitis | [] [/] | |
| Tuberculosis (pulmonary) | 180 [-] | Counselled by TASO? YES[NO.[] |
| Tuberculosis (extra-pulmonary) | [][] | |
| Syphilis | | |
| Other: (specify) | [][] | |
| | 1 | |
| | | (a) (b) |
| | | Name of Clinician. |
| | | and the second s |

Exhibit 7b ISS Clinic Patient Encounter Form, 1998–2005, page 2 of 2

| Mbarara University Tea | ching Hospital | |
|--|---------------------------------------|---------------------------------------|
| Physical Examination Form | <u>Laboratory results</u> <u>Date</u> | <u>:</u> |
| Height (cm) Weight (kg) | Hemoglobin | |
| BMI (wt/ht²) | ESR | |
| Blood Pressure: Temperature: | Cell count total | |
| Chief Complaint: | % Neut: | % Lymph: |
| | % Mono: | % Eos: |
| To a true on the trapelle | Other: | |
| pr. Vinaley. Tra. France. | | |
| no Bland x 2 lday water. | | |
| The same of the same | | YES NO |
| 15 0 Col 1 | Chest X-ray | [] [] |
| Current Medications: | result: | |
| | | |
| DIEM JEDGE | | |
| ~ I ∴ 5° | | |
| | | |
| Physical Examination: | Karnofsky rating: | |
| | | |
| leep | Previous hospitalization | |
| on. () Soller offer | HIV related | |
| in. (It dear | reason: | |
| | Non HIV related | r 1 r 1 |
| | Non-HIV related | |
| J 9 E - (01) | reason: | |
| | Referral for Admission: | |
| | reason: | [] [-1000] |
| The characteristics of | 1643011. | |
| 1 | Treatment: | |
| () | 0 2 - 1 - 1 - 1 | 0- |
| 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 3 (1) | |
| Medan. | (ii) Koracoui, | |
| , | () church | |
| | O Rosadi. | 4 |
| | | |
| | , , | · · · · · · · · · · · · · · · · · · · |

Exhibit 8a Patient Encounter Forms for Access, 2005–2006, page 1 of 2

| | | Intake Form | |
|---|------------------------------|---|--------------|
| Patient Number: Registration Date: PATIENT DEMOGRAPHICS | 3.299 | Patient First Name: Patient Last Name: Form Completed By: | TODES Lamre |
| Date of Birth | - , | Village | 1 MERCHANT |
| Gender Male | Female | 1,7 | 15 - MAROUT |
| Tribe Adda | E | Parish | 13.17 |
| Marital Status: Single | | Subcounty: | 1-7- |
| Married | (1) | District: | As |
| Married | Lamasori | Telephone: | |
| Married | | Occupation: | (1 some |
| Married | - | | Emmon |
| Divorce | BOWNSON . | Transportation Cost: | |
| Widow | numero . | Total Children: | |
| | | ISS Stratus of Children: | |
| TASO Registered? Yes | No No | Non-children Dependents: _ | |
| MEDICAL HISTORY | 1.0-6 | Next of Kin: 1556 | Relation: |
| Date of First NYY Test: | 4 -110 | NVV Test 2: | NYY Test 3: |
| Initial Clinical Suspicion: | HIV Illness: Non-HIV Illness | Blood Transfusion: Y/N: | |
| Current Symptoms | Yes/No | | Yes/No |
| Diarrhoea > 1 month | | Anal Sores | 1911 |
| Fever> 1 month | * | Anal Swelling | IAC |
| Weight Loss >10% | | Genital Sores | on & Off |
| Cough >1 month | | Genital Swelling | 1/210 |
| Skin Rash | | Genital Itching | 7 |
| Deventhoning | 1/210 | Oral Sores | |
| Paresthesias | | Odynophagia | 1910 |
| Ammenorrhoea | | | |
| | | Dysphagia | -17 |
| | Yes/No | Dysphagia | YesiNo |
| Ammenorrhoea Current Signs | YesiNo | Dysphagia Hepatomegaly | |
| Ammenorrhoea Current Signs Oral Thrush | Yes/No | | Yes/No |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair | Yes/No | Hepatomegaly | 100 0000 |
| Ammenorrhoea Current Signs Oral Thrush | Yes/No | Hepatomegaly Splenomegaly | 100 0000 |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation | | Hepatomegaly Splenomegaly Alopecia | 100 0000 |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality | | Hepatomegaly Splenomegaly Alopecia | 100 0000 |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema | yeo 488 80M |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster | | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia | yeo 488 80M |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster Herpes Simplex | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia Viral Warts | yeo 488 80M |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster Herpes Simplex Peripheral Neuropathy | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia Viral Warts Cryptococcal Meningitis | yao ARB SCIM |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster Herpes Simplex Peripheral Neuropathy AIDS Related Dementia | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia Viral Warts Cryptococcal Meningitis Pulmonary TB | yao ARB SCIM |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster Herpes Simplex Peripheral Neuropathy AIDS Related Dementia Kaposi Sarcoma | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia Viral Warts Cryptococcal Meningitis | yeo 488 80M |
| Ammenorrhoea Current Signs Oral Thrush Silky Hair Hyperpigmentation Lymphadenopath Cranial Nerve Abnormality Past Diagnoses Herpes Zoster Herpes Simplex Peripheral Neuropathy AIDS Related Dementia | Yes/No Year | Hepatomegaly Splenomegaly Alopecia Lower Extremity Oedema Anaemia Viral Warts Cryptococcal Meningitis Pulmonary TB Extra -pulmonary TB | yeo 488 80M |

Exhibit 8b Patient Encounter Forms for Access, 2005–2006, page 2 of 2

| | Physical Examina' on | | Form 08, 2004 |
|-----|--|---|---------------|
| | Karnofsky Rating: | d Pressure mperature Hea | rt Rate: |
| | Chief Complaint: | Current Medic | cations: |
| | Congression x lear | | |
| | alod discomfort. | None: | |
| * | , 10 , 1215 Mg | was symptomb. | |
| | | | |
| | Physical Examination | | |
| | Car storing lader a | | ede (|
| | Fac young lady, ao, | Spyrexue | |
| | · N | 0,5, | |
| | At Tolean P/8 Be | ig splien | |
| | 7. | see star Manual | |
| | C | replace sher. | |
| | No | verlyeig skreis. | |
| 2 | | Conacov | |
| | | | |
| I | Diagnosis: (please write specific dx and reason for staging) | Treatment: | |
| | I - 4/0 UTI | | |
| | - 10 arr | / durain s | |
| | | / Muring | |
| | | / · · · · · · · · · · · · · · · · · · · | |
| | | | |
| | | | |
| F | Previous Hospitalisations: | Referral for Admission: | |
| | - I | P/v 2/12. | |
| 100 | | Provider Sim & Klenia | |
| | | (riease | RINT Name) |
| | | | |

Exhibit 9 ART-LINC Budget, October 1, 2007–April 30, 2008

| SUB CATEGORY | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Total |
|------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| | \$ | \$ | \$ | \$ | \$ | \$ | \$ | \$ | \$ |
| IT Manager | 250 | 468 | 468 | 715 | 715 | 715 | 715 | 715 | 4,761 |
| Data Entry Specialist | | 400 | 400 | 603 | 603 | 603 | 603 | 603 | 3,815 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Data Entry Specialist | 250 | 338 | 338 | 495 | 495 | 495 | 495 | 495 | 3,401 |
| Patient Tracker | | 204 | 204 | 204 | 267 | 267 | 267 | 267 | 1,680 |
| Recepitionist Nusre | | | | | | | 344 | 344 | 688 |
| Records Assistant | | | | 63 | 63 | 63 | 63 | 63 | 315 |
| Records Assistant | | | 63 | 63 | 63 | | | | 189 |
| Records Assistant | | | | | 63 | 63 | 63 | 63 | 252 |
| Total - Salaries | 1,750 | 3,100 | 3,163 | 4,618 | 4,744 | 4,681 | 5,025 | 5,025 | 32,106 |
| Health Insurance for 20 pple | - | 690 | - | - | - | - | - | 1,789 | 2,479 |
| Total - Benefits | - | 690 | - | - | • | - | • | 1,789 | 2,479 |
| TOTAL PERSONNEL | 1,750 | 3,790 | 3,163 | 4,618 | 4,744 | 4,681 | 5,025 | 6,814 | 34,585 |
| Communication | | | | | | | | 136 | 136 |
| Travel | | 213 | | | | | | | 213 |
| Study Supplies | 527 | 729 | | 530 | | | | 206 | 1,992 |
| 8% Indirects | 3,024 | | | | | | | | 3,024 |
| TOTAL OPERATIONS | 3,551 | 942 | - | 530 | - | - | - | 342 | 5,365 |
| GRAND TOTAL | 5,301 | 4,732 | 3,163 | 5,148 | 4,744 | 4,681 | 5,025 | 7,156 | 39,950 |

Exhibit 10 WHO Budget

| BUDGET ITEM | ITEM QUANTITY | TOTAL COST |
|--|------------------|---------------|
| Server | 1 | 6,813.00 |
| Uninterruptable power supply (UPS) | 1 | 2,375.00 |
| Generator | 1 | 19,800.00 |
| Photocopier | 1 | 9,255.00 |
| Printer | 1 | 2,260.00 |
| Desktop computer | 5 | 6,100.00 |
| Local area network (LAN) | 1 | 9,346.00 |
| Laptop | 1 | 1,502.00 |
| Internet bandwidth | 12 | 9,600.00 |
| Antivirus software | 1 | 2,500.00 |
| Intercom system | 1 | 4,000.00 |
| PC blower (fan to cool computers) | 1 | 300.00 |
| Flash drives | 10 | 500.00 |
| Toner for printer | 12 | 2,175.00 |
| Ink cartridges for photocopier | 12 | 1,840.00 |
| Chairs | 5 | 212.00 |
| Desks | 1 | 270.00 |
| Photocopying paper and stamps | 50 | 890.00 |
| Volt-ampere (VA) power voltage regulator | 1 | 200.00 |
| Extension cables | 2 | 62.00 |
| TOTAL | | 80,000.00 |

Exhibit 11a Initial Adult Patient Encounter Form, Developed May 2008 (page 1 of 4)

| Patient ID: | | | ART | Number: | | |
|---------------------------------|--------------------------------|---------------------------------|-----------------------------|---|--|--|
| Surname: | | | Othe | r names: | | |
| Patient Catego | ory: 🔲 Ne | w □ Transfe | er in | | | |
| Treat category: | □ N/A □ Widow | ☐ Orphan careta ☐ Spouse of poo | | alth worker RC transfer | ☐ Poor woman ☐ Other: | □ Pregnant |
| Sex: | ☐ Male ☐ Fe | emale | | Date of birth (dd/m | m/yy): / / | or Age : |
| | District: | | | Sub County/Divisi | on: | |
| Patient address: | Parish/Ward: | | | Village/LC1: | | |
| | Phone number | ·. · | | Landlord Name: | | |
| Treatment | Surname: | | Other name | •: | Phone no.: | |
| Supporter: | Relation to pati | ient: □ Spouse □ | l Other family me | ember 🗆 Friend | ☐ Other: | |
| Education: | ☐ none Primar | y: O entered O compl | | dary: O entered O com | | red O completed |
| Occupation: | ☐ Unemployed ☐ Other: | d □ Student | ☐ Civil serva | nt ☐ Business | ☐ Armed forces | ☐ Farmer |
| Tribe: | | Nkole □ Hima | ☐ Ganda | □ Toro □ Konio | ☐ Other: | |
| Religion: | ☐ Catholic | ☐ Protestant | ☐ Mosle | m □ Othe | | |
| Monthly incom | | | 100,000 - 250, | | 250,001 - 500,000 | □ >500,C |
| | | nside your home? | □Yes | □ No | 20.75.01 | |
| Care entry point: | □ RTC (# | | O Outpatient □ CBO □ P | O Inpatient rivate □ Self Referra | O TB Ward | |
| Time needed t | | ☐ less than 3 | 0 minutes □ | | 1-2 hrs □ 2-3 hou | rs |
| Disco sometime and | ou circumcised | | If yes, at what | | If no, would you con | nsider? □ Yes □ No |
| - | sitive HIV test: | | | 3 | , | |
| Where was the | | (mm/yyyy) □ AIC | / Cover | nment facility | ☐ Private facility | ☐ Other |
| TOWERS BY FIRST | | | | Status Divorced | t return for care in fut ☐ Widowed | ture? □ Yes □ |
| Current marita | | ☐ Married Fo | or men if marrie | d: How many wives | do you have?: | |
| HIV status of s Discordance | spouse(s): | | At least one Pos | sitive ☐ All N ks known to be HIV n | legative □Unknov egative? □ Yes | <u>wn</u> □ No |
| Have you disc status to anyo | | ☐ No ☐Yes, if yes | s whom (mark a | ##################################### | use 🗆 Other sex | |
| | al children still | | | | en < 18 years still livi | ng: |
| | ient, how many | | No. HIV-po | | No. HIV status | Control of the Contro |
| | luding children | at school? | | sitive and in care: | No. under 5 ye | |
| N: | ames | | Age | Relationship | Clinic where | cared for |
| House- | | | | | | |
| hold members | | | | | | |
| in HIV | | | + + | | | |
| care: | | | | | | |
| | | | | | | |
| Are ventue | anto an Irain ar | v form of fourth ! | anning /== a=l | I that annive . E M | A (not sexually active) | |
| ☐ Oral contract | na alikan nami-likuman maa and | | | planning / rhythm | | ☐ none ilization/hvsterectom |
| ☐ Diaphragm/c | | | □ Injectible horm | ones (e.g. Depo-provera, I estions (AUDIT-3) | | , |
| | | k containing alcoh | ol in the last ye | ar? | | |
| □ Nev | er 3 times a week | | hly or less times a week | | mes a month re times a week | |
| 27 1000 000000 | | 7.17.71.44.44.45. | | | re times a week drinking in the past ye | ear? |
| □ 0 dı | | ☐ 1 to 2 drint | | 3 to 4 drinks | g are past ye | |
| | 6 drinks | ☐ 7 to 9 drin | | 10 or more drinks | | |
| | | mara drinke on on | o occasion in t | he nast vear? | | |
| How often did ☐ Nev | | ess than monthly | ☐ Monthly | □ Weekly | ☐ Daily or almo | CONTRACTOR OF THE |

Exhibit 11b Initial Adult Patient Encounter Form, Developed May 2008 (page 4 of 4)

| [WHO | STAG | E 1 | | | | |
|----------|----------------|--|--|-----------------|-----------|--|
| | 700 | C 4 | | Due | C | |
| Pre | Cur | \A/= =+i | dunus a | Pre | Cur | At wind this base winds |
| | | Wasting Syr | | - | | Atypical leishmaniasis |
| | | Extrapulmor | nary TB (includes treatment phase) | | | Lymphoma (includes treatment phase) |
| | | | al ulcers (HSV) > 1 month duration | | | Recent septicemia |
| | | | or CMV in other organ system | | | Recurrent bacterial pneumonia |
| | | PCP pneum | E011180 | | | HIV encephalopathy |
| | | Esophageal | | | | Progressive multifocal leukoencephalopathy |
| | | Kaposi's sar | coma (includes treatment phase) | | | Disseminated non-tuberculous mycobacteria |
| | | CNS toxopla | | | | Cryptosporidiosis or isosporiasis |
| | | Cryptococcal n | neningitis/disseminated (inc treatment phase) | | | Disseminated mycosis |
| | | Invasive cer | | | | Symptomatic HIV-nephropathy, cardiomyopathy |
| Other | | 19 | W. O. F. W. V. | - 1 | | |
| Diagn | | 1. | | 2. | | |
| | urrent | 3. | | 4. | | |
| Probl | em | | | - | | |
| List | | 5. | | 6. | | |
| | | | | PLAN | | |
| ARV | Plan: | | | | | tick all applicable) |
| | | e current | | 1100 | | |
| | | o ourrone | ☐ no indication | er until " | TR treat | tment □ patient refusal □ on hold for toxicity wash-o |
| m N | lo ARV | 's | | herence | | |
| "" | | = | Control of the Contro | oporter p | | |
| ПО | tart init | ial regimen 🗼 | | - , - 0 . 0 . 0 | | |
| | le-star | | . □ Clinical □ CD4() [| JTLC(_ | | _) 🗆 pMTCT 🗆 PEP |
| | look | | □ Other: | | | and the second |
| 85 | | | | | | NAME OF THE PARTY |
| | witch | | Failure: ☐ clinical failure ☐ immunolo | | | |
| □s | top | / | | | | ☐ diarrhea ☐ liver toxicity ☐ peripheral neuropathy |
| | | | | oodystro | | ☐ rash ☐ dizziness |
| | | | Misc: ☐ poor adherence ☐ pregnanc | y 🗆 sto | CKOUT | Li new 18 tx Li finished pivi1C1 |
| - | | | Other, specify: | | NIVID (m. | nevirapine) |
| A DV | | | dovudine) □ CBV (AZT/3TC) | | | |
| ARV | | The second secon | mivudine) ABC (abacavir) | | | favirenz) Other: |
| Regi | men. | | (stavudine) | | | (lopinivir/ritonivir or Aluvia) |
| Daniel | | DDI (di | | | | ne 30 (D4T/AZT/NVP) |
| Prov | CHIEF CARLES A | □ MOH | □ MJAP □ TREAT □ FTF | ш | ASO | □ Other: |
| | nseling | 100 100 000 100 | | _ | | Supervisore in the December 1997 in the December 19 |
| □No | ne | | Pre ART | | | nce/ongoing |
| | | | none 🛘 septrin proph 🗖 dapsone proph | | | |
| OI PI | an: | | none 🗆 SRHZE 🗆 RHZE 🗆 EH 🗆 RHE 🗆 R | | □ other | r: 🗆 stop |
| | | CCM 🗆 | none □ diflucan prop □ diflucan tx □ | other: | | ☐ stop (Why?:O improvement O toxic |
| | | 1. | | 2. | | |
| Othe | | 2 | | 4. | | |
| Medi | cation | 5. 5. | | 6. | | |
| Tests | • | 5. □ CD4 | ☐ Viral load ☐ creatinine | | LT/AST | Γ/ALP □ CXR □ sputum AFB |
| orde | | □ CBC | ☐ urine HCG ☐ urinalysis | | PR/VDF | |
| loide | ieu. | ☐ Others: | | | | TC = Stool = Ilpid profile |
| 1 | | L Juliers. | | | | |
| 1 | | | | | | |
| Trans | sferred | out: 🗆 no | □ yes: transferred to: | | | |
| Refe | | □ no | ☐ yes: referred to: | | | |
| | ission: | | | RSIGVN | □ ne | ychiatry □ emergency □ surgical |
| Adili | 1551011. | LI HOHE | □ IIIedicai Waid □ IB □ ∪ | 00/0114 | □ psy | yernatiy — emergency — surgical |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| | | | | | | |
| 1 | | | | | | |
| 1 | | | | | | |
| \vdash | | | | | | |
| Nove | echad | uled appoint | ment date: / / | р | rovider | r name: |
| HEYL | JUILER | area appoint | mone date. | | JVIGE | i name. |

Exhibit 12 Screenshot of an Electronic Form in OpenMRS, ISS Clinic




Exhibit 13 Sample Patient Summary Sheet

Mbarara University Of Science & Technology Department Of Internal Medicine P.O. Box 1410 Mbarara Uganda Tel. 256-485-21623 Fax. 256-485-20782



Mbarara Regional Referral Hospital P.O Box 40 Mbarara Uganda Tel. 256-485-20007

John, Doe

Clinic Id: XXXX-XX-XXXX

Female, 36yrs Art number: KK-YYYY

Address: Rwakirore, Kikokwa, Birere, Isingiro

Last seen on: 18 Jun 2008 by: Jane, Jones

Who stage:Toxicities:Current art regimen:Tb status:Other drugs:AZT/3TC/NVPOther diagnoses:Previous Regimen(s):Allergies:Duration(months): 49/49

First line Substitution(s)

Date Reason

Second line Substitution(s)

Date Reason

| ~ | VITALS | | | | | | | | | | | | |
|------------------------|--------|-------------|----------------|-----------------|--|--|--|--|--|--|--|--|--|
| | Weight | Temperature | Blood Pressure | Karnofsky score | | | | | | | | | |
| Enrollment 27 Feb 2007 | 46 | 37.7 | 100/60 | 90 | | | | | | | | | |
| Art start 24 Apr 2007 | 58 | 36.5 | 110/80 | 90 | | | | | | | | | |
| 12 Mar 2008 | 62 | 36.1 | 100/80 | 80 | | | | | | | | | |
| 30 Apr 2008 | 55 | 36.4 | 88/53 | 90 | | | | | | | | | |
| 18 Jun 2008 | 62 | 36.2 | 80/60 | 80 | | | | | | | | | |

| DRATORY RESU | LIS |
|-----------------------------------|-----------------------------|
| Haemoglobin | Viral load |
| 8.2 27 Mar 2007 10 23 Jan 2008 | |
| | Haemoglobin 8.2 27 Mar 2007 |

| OPPORTUNISTIC INFECTION MEDICATIONS | | | | | | | | | |
|--|-------------|-----------|--|--|--|--|--|--|--|
| Drug | Start date | Stop date | | | | | | | |
| Cpt/Dapsone | 27 Feb 2007 | | | | | | | | |
| Fluconazole | | | | | | | | | |
| Tb rx | | | | | | | | | |

Alert! Please Repeat Cd4!

Printed on: May 23, 2011 9:10 AM

Exhibit 14a Results of Mbarara Time-Motion Study: Providers

| Measure | Before Summaries | After Summaries | Before-After Difference |
|----------------------------|-------------------------|-----------------|-------------------------|
| Number of physicians | 3 | 3 | 0 |
| Number of clinic hours/day | 6.5 | 6.4 | -0.1 |
| Number of patients/day | 41 | 44 | 3 |
| Direct patient care (%)* | 25.7 | 34.6 | 8.9 |
| Indirect patient care (%) | 35.6 | 33.2 | -2.4 |
| Administration (%) | 6.0 | 8.8 | 2.8 |
| Personal (%) | 14.5 | 13.3 | -1.2 |
| Miscellaneous (%) | 16.7 | 6.6 | -10.1 |
| Waiting (%) | 1.4 | 3.4 | 2.0 |

^{*}Time is measured in percent of a provider's workday. No between group differences were statistically significant (p-value <0.05)

Exhibit 14b Results of Mbarara Time-Motion Study: Patients*

| Measure | Before Summaries n = 88 | After Summaries n = 94 | Before-After Difference |
|--------------------------|----------------------------|---------------------------|-------------------------|
| Time in registration | 1.2 | 1.0 | -0.2 |
| Time with clinicians | 7.7 | 6.4 | -0.7 |
| Time with other staff | 42.3 | 61.3 | +19.0 |
| Time with pharmacy | 1.7 | 11.6 | +9.9 |
| Miscellaneous activities | 22.9 | 17.9 | -5.0 |
| Waiting | 121.9 | 88.0 | -33.9 |
| Waiting for registration | 0.3 | 0.0 | -0.3 |
| Waiting for clinicians | 45.1 | 44.5 | -0.6 |
| Waiting for other staff | 52.4 | 28.9 | - 23.5 |
| Waiting for pharmacy | 24.1 | 14.6 | -9.5 |
| Total visit time | 197.7 | 186.2 | -11.5 |

^{*}Time is measured in minutes per patient visit observed. Statistically significant differences (p-value <0.05) are indicated by shading.

Source: Were M, Shen C, Bwana M, et al. Creation and evaluation of EMR-based paper clinical summaries to support HIV-care in Uganda, Africa. *International Journal of Medical Informatics*. 2010;79:90-96.

Exhibit 15a Provider Satisfaction with Clinical Summaries





Exhibit 15b Desirability of Elements in Clinical Summaries Among Practitioners



Source: Were M, Shen C, Bwana M, et al. Creation and evaluation of EMR-based paper clinical summaries to support HIV-care in Uganda, Africa. *International Journal of Medical Informatics*. 2010;79:90–96.

Exhibit 16a Ministry of Health's HIV ART Form, August 2009, page 1 of 2

| | A. Carrier | | | | | Drug allerg | es | | | Relevant | medical o | onditio | ns |
|--|--|-----------------------------------|---|------------------|-----------------|---|----------------------------|---|--|--------------|---------------------------------|-----------------|-----------------|
| | HIV CARE/AR | T CARD | | | | | | | ART C | are | COHORT | : MM | YYYY |
| ue # | | | | | | Date | | | | | | | |
| ct | Health unit | Clinical tea | | | | | 0 DT 4 | for in from | | | A D | V/o | |
| 0:s | rnone | Given name | Pt clinic # | | | (dd/fnmfyyy) | AK I trans | iter in iron | 1 | | AR | VS | |
| M 🗆 F 🗆 DO | OB (dd/mmfvyyy) | Age Ma | rital status | | | (dd/shmdvyy) | | 1st-line in | itial regir | men | | | |
| ess District | | | County | | | At start A | RT: Wt_ | c | I. Stage_ | | CD4 | Pro | eg |
| Parish hone (whose): | | LC1_ | | | | 1 1 S | ubstitu | te withir | 1st-lir | ne | | | |
| | | | | | | | | | | | | Why | |
| entry point: | □ PMTCT □ TB □ Under □ Medical □ STI □ Inpatio | r 5 □ Outreach ent □Exposed ir | fant ——— | ресіту | | (dal/mm/yyy) | | | | | | _ Why | |
| ment support | er/med pick-up if ill: | | | | _ | 177 | | | e (or s | ubstitut | te withir | | |
| ess District | | Sub-Coun | ty | | | (dalmmhyyy | | | | | | Why_ | |
| phone (whose) | | LC1 | | | | (dd/mm/vvv) | New regin | nen | | | | vvny | |
| e-based care p | | | | | | APT | traatman | t interrupti | one - ST | OP or mie | sed drug p | niek-un | |
| | Age HIV HIV Unique no. | Exposed | infant follo | W-UD | | Stop or Lost | Stop | Stop | Stop | Stop | Stop | Stop | Stop |
| ers and | P/N care Y/N/U | | Infant CTX | | (if confirm | (circle) | Lost | Lost | Lost | Lost | Lost | Lost | Lost |
| 15 | med | Exposed infant (Name/II) DOB | feeding starte practice d by 2 at 3 mos mos | HIV Final status | +) Unique ID | Date | (dd/mmfysys) | (dd.lmmlyyyy) | (ddkmmhyyyy | (uchambsss | (ddfmmfyyyy) | (dalmmlyyy) | e, edalminifysy |
| | | | at 3 mos mos | Presuit | | Why | | | | | | | |
| | | | | | | Date if restart / re-activated | (dd/mm/yyyy) | (ddfnmhyyy) | (dd/mm/yyyy | (dahimhyyy | (ddfmmfyyy) | (ddfmmhyy) | r (ddfmofry) |
| | | | | | | 7 re-activated | Ct-t | | I D - t - | | _ | | |
| | | | | | | Transfer o | Status | | Date | (mm4yyyy) | Where | , | |
| | | | | | | Lost to foll | | lrop) | | mmdryyy) | VVIIOTO | | |
| | fes □ None □ | | 1.1 | | | Dead | | | (dd) | (mmdyyyy) | | | |
| Prior ART | | | | | - | Infant Feeding F Exclusive Breast Replacement Fee | ractice on in | fant cards: | | 7 | Why STO | D codes | |
| PEP PMTCT only | (dd/mm/yyyy) Where | | RVs | | | Replacement Fee Mixed Feeding | ding: | | | 1 To: | xicity/side et | | |
| Earlier ARV not transfer | (ad/mm/lyyy) Where | | lVs | | | HIV-exposed in | ant final sta | tus at 18 mo | onths: | 2 Pre | egnancy | | |
| not transfer | (advamayyyy) vviidie | | .05 | | | DEAD if dead (w P if positive N if i | egative and | no longer bre | wn) east feeding | | eatment failu or adherenc | | |
| are | Date | | | | | N/BF if negative U if status unkno | and still brea | st feeding | | 5 Ilin | ess, hospita | lization | |
| med HIV+ test | | | | | | Why SUBS | TITUTE or | SWITCH co | des: | | ugs out of st tient lacks fi | ock nances | |
| nrolled | (ddfmm/lyyy) HIV care tra | ansfer in from _ | | | | 1 Toxicity/side 2 Pregnancy | effects 7 | Other reasons for S | on (specify) | 8 Ott | ner patient o | lecision | |
| le for ART | (dcfmm/lyyy) Clinical stage_ | | | | | | | | | | | erruption | |
| | (dammyyyy) Omnour stage_ | | CD4 | | | 2 Pregnancy 3 Risk of preg | nancy 2nd | d-line regin | nen only: | 10.0 | ther (specifi | () | |
| le and ready | ☐ Presumptive | e clinical HIV dia | CD4 gnosis of se | vere HIV i | nfection | 3 Risk of preg 4 Due to new 5 New drug av | rB 8 | d-line regin Clinical fails Immunolog | nen only: ure ic failure | 10.0 | ther (specification) | () | in infant |
| le and ready | □ Presumptive | e clinical HIV dia | CD4 gnosis of se | vere HIV i | nfection | 3 Risk of preg 4 Due to new 5 New drug av 6 Drug out of | rB 8 | d-line regin Clinical faild Immunolog | nen only: ure ic failure | 10.0 | ther (specifi | () | in infant |
| le and ready | ☐ Presumptive | e clinical HIV dia | CD4 gnosis of se | vere HIV i | nfection | 3 Risk of preg 4 Due to new 5 New drug av 6 Drug out of | rB 8 | d-line regin Clinical faild Immunolog | nen only: ure ic failure | 10.0 | ther (specifi | () | in infant |
| le and ready | ☐ Presumptive in infant | × | gnosis of se | | | 5 New drug av 6 Drug out of | TB 8 ailable 9 stock | Clinical failu Immunolog | nen only: ure ic failure | 10.0 | ther (specifi | () | in infant |
| le and ready | ☐ Presumptive in infant | e clinical HIV dia | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: ure ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | (dchmmdyyyy) □ Presumptive in infant | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | TB 8 ailable 9 stock | Clinical failt Immunolog | nen only: ire ic failure | 10 O 11 E | ther (specifi | () infection | in infant |
| | (dchaml/9999 Presumptive in infant | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | (dchmmdyyyy) □ Presumptive in infant | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: ire ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | (dchaml/9999 Presumptive in infant | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: ure lo failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | Presumptive in infant | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: ure ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant Presumptive in infant Funducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling: implications of results | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: ure c failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | Presumptive in infant F inducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results | × | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: tre ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant Presumptive in infant F ducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: tre ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant Funderation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results g g ners to whom disclosed (list) | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant F siducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results g so whom disclosed (list) situation | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant Presumptive in infant F aducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results g ners owhom disclosed (list) situation identiality | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: Ire ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| | resumptive in infant Funducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results g ners to whom disclosed (list) situation identiality e choices, prevention MTCT | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: Ire ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV et Prevention: In Prevention: In Prevention: In Prevention: In Testing part of the Post I be a prevention of the Prevention: In Testing part of th | ducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results g ners to whom disclosed (list) situation identiality de choices, prevention MTCT (test | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | een only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV e Prevention: Prevention: Post-test coordinate Post-test coord | Presumptive in infant F Inducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results general conductions of the state of disease. Presumptive in infant F Inducation transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results general conductions of the safe in infant i | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | en only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV e Prevention: Preven | Presumptive in infant Formula of the infant | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | en only: re ic failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV et Prevention: Prevention: Prev | Presumptive in infant F situation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results 9 ners to whom disclosed (list) situation identiality e choices, prevention MTCT t test of disease ention, IPT, ITN atment/prophylaxis (CTX) | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | en only: re failure | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: In Basic HIV e | recommendation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g ners to whom disclosed (list) situation dientiality de choices, prevention MTCT t test of disease ention, IPT, ITN atment/prophylaxis (CTX) appointments, clinical team | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV et Prevention: Preve | resumptive in infant Framework in infant Framewor | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV et Prevention: Preve | recommendation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g ners to whom disclosed (list) situation dientiality de choices, prevention MTCT t test of disease ention, IPT, ITN atment/prophylaxis (CTX) appointments, clinical team | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrainable tre- ART put | resumptive in infant Framework in infant Framewor | ¥ | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrainable tre- ART put | resumptive in infant Formula of the infant | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | Presumptive in infant Finducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling: implications of results g | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | ducation, transmission abstinence, safer sex, condoms household precautions, what is safe unsellings: implications of results g ners to whom disclosed (list) situation identiality e choices, prevention MTCT t test of disease entition, IPT, TIN atment/prophylaxis (CTX) prointments, clinical team ate on essentials (locally adapted) te adherence needed preparation, indicate visits in READY for ART: DATE/result Clinic | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne control con | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | reducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g ners to whom disclosed (list) situation identiality de choices, prevention MTCT I test of disease ention, IPT, ITN atment/prophylaxis (CTX) oppointments, clinical team also on essentials (locally adapted) te acherence needed reparation, indicate visits on READY for ART: DATE/result Clinics, when to take | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | Presumptive in infant Finducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results geners owhom disclosed (list) situation identiality e choices, prevention MTCT t test of disease ention, IPT, TN atment/prophylaxis (CTX) pointments, clinical team ate on essentials (locally adapted) te adherence needed reparation, indicate visits n, when to lake our, how to manage side effects (one lorgets dose | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nemonity: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | Presumptive in infant Finducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling: implications of results g g stansmission dentiality schoices, prevention MTCT t lest of disease ention, IPT, ITN atment/prophylaxis (CTX) oppointments, clinical team ate on essential (locally adapted) te acherence needed preparation, indicate visits in READY for ART: DATE/result Clinic b, when to take curr, now to manage side effects fore forgets dose when traveling | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Family/living Reproductive Progression Available tre- Polive with Arrange ART — educt Why complete | ducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g mers to whom disclosed (list) situation dentiality de choices, prevention MTCT I test of disease entition, IPT, ITN atment/prophylaxis (CTX) oppointments, clinical team ate on essentials (locally adapted) the acherence needed proparation, indicate visits in READY for ART: DATE/result Clinic to, when to take curr, now to manage side effects one forgets dose when travelling blan (schedule, aids, explain diary) | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne control con | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Family/living Reproductive Reproductive Progression Mariar prevention ART Prevention: Why complete Explain dose What do di What do di What do di What to do if What to do if What to do if What to do if Treatment at Treatment a | reducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling; implications of results g ners to whom disclosed (list) situation identiality test of disease ention, IPT, ITN attentior polyplaxis (CTX) spointments, clinical team attent/prophylaxis (CTX) spointments, clinical team attent/prophylaxis (cTX) test of mr. READY for ART: DATE/result Clinic teacherace needed preparation, indicate visits to mr. READY for ART: DATE/result Clinic to, when to take cour, how to manage side effects fone forgets dose when to reveal the proper side of the court of the proper side of the court of the | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Basic HIV e Prevention: Prevention: Prevention: Prevention: Feating part of the prevention | recommendation in infant Framework in infant Fram | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | nen only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV et prevention: Prevention: Testing part Test | Presumptive in infant Finducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results geners o whom disclosed (list) situation identiality e choices, prevention MTCT t test of disease ention, IPT, TIN atment/prophylaxis (CTX) pointments, clinical team ate on essential (locally adapted) te acherence needed preparation, indicate visits in READY for ART: DATE/result Clinic o, when to take cour, now to manage side effects fone forgets dose when traveling dise, explain diary) upporter preparation o, why missed t group | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV et prevention: Prevention: Testing part Test | ducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g mers to whom disclosed (list) situation dentiality de choices, prevention MTCT t est of disease entition, IPT, ITN atment/prophylaxis (CTX) atment/prophylaxis (CTX) pointments, clinical team ate on essentials (locally adapted) the atherence needed preparation, indicate visits in READY for ART: DATE/result Clinic to, when to take curf, now to manage side effects to no forgets dose when traveling bian (schedule, aids, explain diary) upporter preparation s, why missed t group act clinic | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne conjugate de la conjugate d | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV et prevention: Prevention: Testing part Test | Presumptive in infant Finducation, transmission abstinence, safer sex, condoms household precautions, what is safe unseiling: implications of results geners o whom disclosed (list) situation identiality e choices, prevention MTCT t test of disease ention, IPT, TIN atment/prophylaxis (CTX) pointments, clinical team ate on essential (locally adapted) te acherence needed preparation, indicate visits in READY for ART: DATE/result Clinic o, when to take cour, now to manage side effects fone forgets dose when traveling dise, explain diary) upporter preparation o, why missed t group | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne control con | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV et prevention: Prevention: Testing part Test | reducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g ners to whom disclosed (list) situation identiality denticality test of disease ention, IPT, ITN alment/prophylaxis (CTX) popiniments, clinical team ate on essentials (locally adapted) te adherence needed repearation, indicate visits on READY for ART: DATE/result Clinic to, when to take out, now to manage side effects one forgets done the individual of the individual | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | re reliable to the reliable to | 10 O 11 E | ther (specifi xcluded HIV | () infection | in Infant |
| Basic HIV e Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Prevention: Feating part Testing part | reducation, transmission abstinence, safer sex, condoms household precautions, what is safe unselling; implications of results g ners to whom disclosed (list) situation identiality denticality test of disease ention, IPT, ITN alment/prophylaxis (CTX) popiniments, clinical team ate on essentials (locally adapted) te adherence needed repearation, indicate visits on READY for ART: DATE/result Clinic to, when to take out, now to manage side effects one forgets done the individual of the individual | collow-up ed | gnosis of se | upport a | | 4 Due to new 5 New drug av 6 Drug out of | aliable 9 stock | Clinical failt Immunolog | ne only: | 10 O 11 E | ther (specifi xcluded HIV | () infection | in infant |

Exhibit 16b Ministry of Health's HIV ART Form, August 2009, page 2 of 2

| Date Check if cheduled. Write in | Follow- up date | Duration in months since first starting ART/ | Wt | If Pregnafé EDD? PMTCT? Write gestation in weeks and ANC # | TB status | | Potential SIDE EFFECTS | Other | Functiona | WHO clinical stage | CPT | Other meds dispensed (including nutritional | | | ARV (incl. pro | | Inves | stigations | consult or link/provide | Name of attend |
|--|--|--|---|--|--|---|--|--|------------------|--------------------------|--|---|------------------|----------|--|------------------------------------|---|--|--|-------------------|
| ernate -up if ill | | ART/ since starting current regimen | Ht | If FP write method(s) | If TB Rx start /sto date (mm/yyyy | | | If child, include nutritional problems | Work/ Playing | | | supplements/ RUTF) | | | | | CD4 If < 5, | Hgb, RPR, CXR, TB | (including nutritional support and infant/leeding) | |
| | | | If child (0-5yrs) record +/- oedema | MUAC If <u>child</u> Write age in months if ≤5 yrs | and Distric | at | | problems | Amb Bed | | Adhere Dose/# of days Dispensed | | Adh | ere/ | Regimen/ Dose/# of days dispensed | | If < 5, record CD4% +/- sewere | sputums, Infant Ab/PCR, other | If hospitalized, # of days | |
| | | | Wt | | TB Stat | 15 | | | | | | | | | REGI | MEN | | | | |
| | | | Ht Oedema | | mm/y | | | | | | 1 | | ADH | Why | DO: | | | | | |
| | - | | Wt | | TB Stat | - | | | | 4. | | | + | | No. of | | | | | |
| _ | | | Ht | | mm/y) | | | | | | | | ADH | Why | D09 | | | | | |
| | | - | Oedema Wt | | Reg No TB State | | | | | | | | - | | No. of | | | | | , |
| | | | Ht | | mm/yı | | | | | | | | ADH | Why | DOS | - | | | | |
| - | | | Oedema | | Reg No | | | | | | | - | - | | No. of | | | | | |
| | | | Wt Ht | | TB Stati | | | | | | | | ADL | Why | - REGI | | | | | |
| | | | Oedema | | Reg No | | | | | | | | ADI | Willy | No. of | | | | | |
| | | | Wt | | TB State | IS . | | | | | | | | | REGI | | | | | |
| | | | Ht Oedema | | mm/yy Reg No | | | | | | | | ADH | Why | No. of | | | | | |
| | | | Wt | | TB Statu | | | | | | | | | H | REGI | | | | | |
| | | | Ht Oedema | | mm/yy Reg No | | | | | | | | ADH | Why | DOS | | | | | |
| | | | Wt | | TB Statu | | | | | | | | - | | No. of REGII | | | | | |
| | 3 | | Ht | | mm/yy | | | | | | | | ADH | Why | DOS | E | | | | |
| П | | | Oedema Wt | | Reg No TB Statu | | | | - | | | - | - | \vdash | No. of REGII | | | | | |
| | | | Ht | | mm/yy | | | | | | | * | ADH | Why | DOS | | | | | |
| _ | | | Oedema | | Reg No | | | | _ | | | | _ | | No. of | _ | | | | |
| | | | Wt Ht | | TB Statu mm/yy | S | | | | | | | ADH | Why | REGI/ DOS | - | | | | |
| | | | Oedema | | Reg No. | | | | | | | | | | No. of | Days | | | | |
| | | | Wt | . | TB Statu mm/yy | S | | | | | | | ADH | un | REGI/ DOS | | | | | |
| | | | Oedema | | Reg No. | | | | | | | | KUH | winy | No. of | | | | | |
| | | | Wt | | TB Statu | s | | | | | | | | | REGIN DOS | | | | | |
| | | | Oedema | | mm/yy Reg No. | | | | | | | | ADH | Why | No. of | | | | | |
| | | | Wt Ht | | TB Statu | S | | | | ×. | | | | - | REGIA | AEN | | | | |
| | | | Dedema | | mm/yy Reg No. | 7 | | | | | | | ADH | Why | No. of | | - | | | |
| | | | Wt | | TB Statu | s | | - | | | | | | | REGIN | | | | | |
| | - | | Ht Dedema | - 14 | mm/yy Reg No. | | | | | | | | ADH | Why | No. of I | | | | | |
| | | | Wt | | TB Statu | 5 | | | | | | | | + | REGIA | | | | | |
| | | | Ht | | mm/yy | | | | | | | | ADH | Why | DOSE | | | | | |
| | | | Dedema Wt | | Reg No. TB Statu | | | | - | | - | | _ | - | No. of I | | | | | |
| | | | Ht | | mm/yy | | | | | | | | ADH | Why | DOSE | | | | | |
| _ | , | | Dedema Wt | | Reg No. | | | | | | | | | | No. of I | | | | | |
| | | | Ht | | TB Statu mm/yy | | | | | | | = | ADH | Why | REGIA | - | | | | |
| _ | | | Dedema | | Reg No. | | | | | | | 1 | | | No. of E | _ | | | | |
| | | | Ht | | TB Statu: | | | | | | | | ADH | Why | REGIN | | | | | |
| - | | 0 | Dedema | | Reg No. | | | | | | | | | 1 | No. of I | | | | | |
| | | | Wt | - | TB Statu: mm/yy | | 47 | | | * | | | ADH | Why | REGIN DOSE | - | | | | |
| | | (| Dedema | | Reg No. | | | | | | | | 11211 | | No. of E | | | | | |
| child P = f If pre PMT in we FP= If usin | nancy/fam dbearing ag Pregnant gnant, give CT if referre seks and Ah Not pregna ng FP, note ded) | e estimated ed to PMTC VC # nt and on fa methods (no | due date T and re amily pla te: more | e (EDD), wr ecord gesta nning than 1 meth | ite tional age | Therapeuti Infant Fee Nutrition C Food Supp problems Nausea Diarrhoea Fatigue changes | ding Courselling ourselling out Rash Anae ABd | nselling (if <2 yr only (if > 2 yr nsemia ominal pain | vrs) | che Dice W | oster neumonia Ementia/Ei hrush—ora OUGH* EVER B difficult b /eight loss* ID pelvic in | reathing discharge | | ns: | | % Adhe | re = otal no. of the drugs | in the regimen | en: x 100 to have been tak | per month |
| 1 No 2 Su sent 3 TB i) mo | es for TB s signs = no spect = TB & results in Rx = curre enth/year sta | refer or sp lab column ntly on TB to arted and st | mptoms utums so record reatmer | of TB ent (Record referral in I it. Record | Refer col) | Codes fo | r Family F | nightmare, d | epress | ion G | Icers_mou IUD genital RIS Immune ymptoms w Ok | th or other ulcer disease reconstitution inf ith * are suggestiv | lamma re of T | Breen | yndrome | 2 Share v 3 Forgot 4 Felt be | vith others | or/ fair adherents | 9 Delivery/trave 10 Inability to pa 11 Alcohol | el problems ay |
| ii)dis (Rec | trict TB reg ord INH in I meds col) | # NH col and | TB trea | tment regin | nen in | 2 Oral Contr 3 Injectable (depoprove 4 Diaphram | aceptive pills / Implantable era) | hormones e.g | | I N | Moderate Adultievere Acut | cute Malnutrition e Malnutrition e Malnutrition with | - Ye | llow | | 5 Too ill | disclosur | e | 12 Depression 13 Pill burden 14 Lack of food 15 Other (spec | 1 |

Exhibit 17 Peer-Reviewed Articles from ISS Clinic, 2006–2010

1. Andia I, Kaida A, Maier M, Guzman D, Emenyonu N, Pepper L, et al. Highly active antiretroviral therapy and increased use of contraceptives among HIV-positive women during expanding access to antiretroviral therapy in Mbarara, Uganda. *Am J Public Health*. 2009 Feb;99(2):340–347.

- 2. Baker CAR, Emenyonu N, Ssewanyana I, Jones NG, Elrefaei M, Nghania F, et al. Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. *AIDS Res. Hum. Retroviruses*. 2007 Jul;23(7):900–905.
- 3. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? *AIDS*. 2006 Jan 2;20(1):140–141; author reply 141–142.
- 4. Bousheri S, Burke C, Ssewanyana I, Harrigan R, Martin J, Hunt P, et al. Infection with different hiv subtypes is associated with CD4 activation-associated dysfunction and apoptosis. *J. Acquir. Immune Defic. Syndr.* 2009 Dec;52(5):548–552.
- 5. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. *J. Acquir. Immune Defic. Syndr.* 2010 Mar;53(3):405–411.
- 6. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. *JAMA*. 2008 Aug 6;300(5):506–507.
- 7. Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. *Trop. Med. Int. Health.* 2010 Jun;15 Suppl 1:63–69.
- 8. Geng EH, Bwana MB, Kabakyenga J, Muyindike W, Emenyonu NI, Musinguzi N, et al. Diminishing Availability of Publicly Funded Slots for Antiretroviral Initiation among HIV-Infected ART-Eligible Patients in Uganda. Myer L, editor. PLoS ONE. 2010 Nov 24;5(11):e14098.
- 9. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010 Dec;14(6):1340–1346.
- 10. Haberer JE, Kiwanuka J, Nansera D, Wilson IB, Bangsberg DR. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. AIDS Behav. 2010 Dec;14(6):1294–1301.
- 11. Hahn JA, Bwana MB, Javors MA, Martin JN, Emenyonu NI, Bangsberg DR. Biomarker testing to estimate underreported heavy alcohol consumption by persons with HIV initiating ART in Uganda. *AIDS Behav*. 2010 Dec;14(6):1265–1268.
- 12. Kaida A, Lima VD, Andia I, Kabakyenga J, Mbabazi P, Emenyonu N, et al. The WHOMEN's scale (Women's HAART Optimism Monitoring and Evaluation Scale v.1) and the association with fertility intentions and sexual behaviours among HIV-positive women in Uganda. *AIDS Behav*. 2009 Jun;13 Suppl 1:72–81.
- 13. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. *J. Acquir. Immune Defic. Syndr.* 2009 Oct 1;52(2):280–289.
- 14. Maier M, Andia I, Emenyonu N, Guzman D, Kaida A, Pepper L, et al. Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. *AIDS Behav*. 2009 Jun;13 Suppl 1:28–37.
- 15. Maier M, Bwana M, Emenyonu N, Pepper L, Bangsberg DR. How to Take HIV antiretroviral medications on time without a watch in rural Uganda. *PLoS Med.* 2006 Mar;3(3):e161.
- 16. Martinez P, Andia I, Emenyonu N, Hahn JA, Hauff E, Pepper L, et al. Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in southwest Uganda. *AIDS Behav*. 2008 Jul;12(4):605–612.
- 17. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. *AIDS Behav*. 2010 Aug;14(4):778–784.
- 18. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. *PLoS ONE*. 2010;5(4):e10340.

Exhibit 17b Abstracts of Select Articles Emerging from ISS Clinic

Antiretroviral Initiation Among HIV-Infected ART-Eligible Patients in Uganda (2010)

Background: The impact of flat-line funding in the global scale up of antiretroviral therapy (ART) for HIV-infected patients in Africa has not yet been well described.

Methods: We evaluated ART-eligible patients and patients starting ART at a prototypical scale up ART clinic in Mbarara, Uganda between April 1, 2009, and May 14, 2010, where four stakeholders sponsor treatment—two PEPFAR implementing organizations, the Ugandan Ministry of Health-Global Fund (MOH-GF) and a private foundation named the Family Treatment Fund (FTF). We assessed temporal trends in the number of eligible patients, the number starting ART and tabulated the distribution of the stakeholders supporting ART initiation by month and quartile of time during this interval. We used survival analyses to assess changes in the rate of ART initiation over calendar time.

Findings: A total of 1,309 patients who were eligible for ART made visits over the 14 month period of the study and of these 819 started ART. The median number of ART-eligible patients each month was 88 (IQR: 74 to 115). By quartile of calendar time, PEPFAR and MOH sponsored 290, 192, 180, and 49 ART initiations, whereas the FTF started 1, 2, 1 and 104 patients, respectively. By May 2010 (the last calendar month of observation) FTF sponsored 88% of all ART initiations. Becoming eligible for ART in the 3rd (HR = 0.58, 95% 0.45–0.74) and 4th quartiles (HR = 0.49, 95% CI: 0.36–0.65) was associated with delay in ART initiation compared to the first quartile in multivariable analyses.

Interpretation: During a period of flat-line funding from multinational donors for ART programs, reductions in the number of ART initiations by public programs (i.e., PEPFAR and MOH-GF) and delays in ART initiation became apparent at the a large prototypical scale-up ART clinic in Uganda.

Tracking a Sample of Patients Lost to Follow-up Has a Major Impact on Understanding Determinants of Survival in HIV-Infected Patients on Antiretroviral Therapy in Africa (2010)

Objective: To date, data regarding the determinants of mortality in HIV-infected patients starting antiretroviral therapy (ART) in Africa have been primarily derived from routine clinical care settings practicing the public health approach. Losses to follow-up, however, are high in these settings and may lead to bias in understanding the determinants of mortality.

Methods: We evaluated HIV-infected adults initiating ART between January 1, 2004 and September 30th, 2007 in an ART clinic in southwestern Uganda. Clinical and demographic characteristics were obtained through routine clinical care. In evaluating determinants of mortality, a 'naïve' analysis used only deaths known through routine processes. A 'sample-corrected' approach incorporated, through probability weights, outcomes from a representative sample of patients lost to follow-up whose vital status was ascertained through tracking in the community.

Results: In 3,628 patients followed for up to 3.75 years after ART initiation, the "naïve" approach identified male sex and lower pre-ART CD4 count as independent determinants of mortality. The "sample-corrected" approach found lower pre-ART CD4 count, older age, lower weight and calendar year of ART initiation, but not male sex, to be independent determinants of mortality.

Conclusions: Analyses to identify determinants of mortality in HIV-infected patients on ART in Africa that do not account for losses to follow-up can identify spurious associations and miss actual relationships—both with the potential to mislead public health efforts. A sampling-based approach to account for losses to

follow-up represents a feasible and potentially scalable method to strengthen the evidence available for implementation of ART delivery in Africa.

Understanding Reasons for and Outcomes of Patients Lost to Follow-Up in Antiretroviral Therapy Programs in Africa Through a Sampling-Based Approach (2010)

Objectives: Losses to follow-up after initiation of antiretroviral therapy (ART) are common in Africa and are a considerable obstacle to understanding the effectiveness of nascent treatment programs. We sought to characterize, through a sampling-based approach, reasons for and outcomes of patients who become lost to follow-up.

Design: Cohort study.

Methods: We searched for and interviewed a representative sample of lost patients or close informants in the community to determine reasons for and outcomes among lost patients.

Results: Three thousand six hundred twenty-eight HIV-infected adults initiated ART between January 1, 2004 and September 30, 2007 in Mbarara, Uganda. Eight hundred twenty-nine became lost to follow-up (cumulative incidence at 1, 2, and 3 years of 16%, 30%, and 39%). We sought a representative sample of 128 lost patients in the community and ascertained vital status in 111 (87%). Top reasons for loss included lack of transportation or money and work/child care responsibilities. Among the 111 lost patients who had their vital status ascertained through tracking, 32 deaths occurred (cumulative 1-year incidence 36%); mortality was highest shortly after the last clinic visit. Lower pre-ART CD4+ T-cell count, older age, low blood pressure, and a central nervous system syndrome at the last clinic visit predicted deaths. Of patients directly interviewed, 83% were in care at another clinic and 71% were still using ART.

Conclusions: Sociostructural factors are the primary reasons for loss to follow-up. Outcomes among the lost are heterogeneous: both deaths and transfers to other clinics were common. Tracking a sample of lost patients is an efficient means for programs to understand site specific reasons for and outcomes among patients lost to follow-up.

Source: Abstracts reproduced from bold sources cited in Exhibit 17a.

Appendix Abbreviations

AMPATH Academic Model Providing Access to Healthcare

AMRS AMPATH Medical Record Systems

ART antiretrovital therapy

ARV antiretroviral

DOTS directly observed treatment, short-course

EMR electronic medical record FTF Family Treatment Fund

IDRC Canadian International Development Research Centre
IeDEA International Epidemiologic Databases to Evaluate AIDS

ISS Immune Suppression Syndrome

IT information technology

JCRC Joint Clinical Research Centre
MGH Massachusetts General Hospital
MJAP Mulago–Mbarara Joint AIDS Program

MOH Ministry of Health

MUST Mbarara University of Science and Technology

OpenMRS Open Medical Record System

PEPFAR President's Emergency Plan for AIDS Relief [US]

UCSF University of California, San Francisco

References

1. Bureau of African Affairs, U.S. Department of State. Background note: Uganda. 2011; http://www.state.gov/r/pa/ei/bgn/2963.htm. Accessed May 12, 2011.

- 2. United Nations Development Program. Uganda country profile of human development indicators. 2010; http://hdrstats.undp.org/en/countries/profiles/UGA.html. Accessed May 23, 2011.
- 3. Ministry of Foreign Affairs. Map of Uganda. 2011; http://www.mofa.go.ug/index.php/mapofuganda. Accessed May 23, 2011.
- 4. Ministry of Finance, Planning, and Economic Development. *Millennium Development Goals Report for Uganda 2010*. Kampala2010.
- 5. The World Bank. *Electric Sector Development Project: Project Information Document (PID) Appraisal Stage.* Washington, D.C.2011.
- 6. Niwe M, Mbarika V, Samake K, Niyitegeka M. Global diffusion on the Internet: The Case of Uganda. Paper presented at: AMCIS 2007 Proceedings. Paper 503. 2007.
- 7. World Health Organization. *Mortality country fact sheet* 2006. Geneva2006.
- 8. Bukirwa H, Yau V, Kigozi R, et al. Short report: assessing the impact of indoor residual spraying on malaria morbidity using a sentinel site surveillance system in Western Uganda. *American Journal of Tropical Medicine and Hygiene*. 2009;81(4):611-614.
- 9. The Republic of Uganda, Ministry of Health. Health Sector Strategic and Investment Plan 2010/11 2014/15. Kampala2010.
- 10. Orem JN, Zikusooka CM. Health financing reform in Uganda: How equitable is the proposed National Health Insurance scheme? *International Journal for Equity in Health*. 2010;9(23).
- 11. Gladwin J, Dixon R, Wilson T. Implementing a new health management information system in Uganda. *Health Policy and Planning*. 2003;18(2):214–224.
- 12. Okero FA, Aceng E, Madraa E, Namagala E, Serutoke J. *Scaling Up Antiretroviral Therapy: Experience in Uganda, Case Study.* Geneva: World Health Organization;2003.
- 13. USAID/Uganda. HIV/AIDS Health Profile. USAID, Kampala:2010.
- 14. AIDS Control Programme, Ministry of Health. *Status of Antiretroviral Therapy in Uganda, Quarterly Report for January-March* 2010. Kampala2010.
- 15. Ministry of Health. *Uganda HIV/AIDS Sero-Behavioural Survey* 2004-2005. Calverton, Maryland2006.
- 16. Jha AK, DesRoches CM, Campbell EG, et al. Use of electronic health records in U.S. hospitals. *New England Journal of Medicine*. 2009;360(16):1628–1638.
- 17. Koppel R, Metlay JP, Cohen A, et al. Physician order entry systems in facilitating medication errors. *JAMA*. 2005;293(10):1197–1203.
- 18. Scott JT, Rundall TG, Vogt TM, Hsu J. Kaiser Permanente's experience of implementing an electronic medical record: a qualitative study. *British Medical Journal*. 2005;331:1313–1316.
- 19. The Global Fund to Fight AIDS Tuberculosis and Malaria. *The Global Fund 2010: Innovation and Impact Results Summary.* Geneva2010.
- 20. The U.S. President's Emergency Plan for AIDS Relief. *World AIDS Day 2009: Latest PEPFAR Results.* Washington, D.C.2010.
- 21. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet*. Jul 26 2008;372(9635):293–299.
- 22. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. *Ann Intern Med.* Jan 16 2007;146(2):87–95.
- 23. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. *Ann Intern Med.* Jul 20 2011.

24. Fraser HS, Biondich P, Moodley D, Choi S, Mamlin BW, Szolovits P. Implementing electronic medical record systems in developing countries. *Informatics in Primary Care*. 2005;13:83–95.

- 25. World Health Organization. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach: Executive Summary. Geneva2002.
- 26. Mamlin BW, Biondich PG. AMPATH Medical Record System (AMRS): collaborating toward an EMR for developing countries. Paper presented at: American Medical Informatics Association (AMIA) Annual Symposium 2005; Washington, D.C.
- 27. Regenstrief Institute, Inc. 2011; http://www.regenstrief.org/. Accessed June 16, 2011.
- 28. OpenMRS: frequently asked questions. 2011; http://openmrs.org/about/faq/. Accessed May 19, 2011.
- 29. OpenMRS: mission, values, and vision. 2011; http://openmrs.org/about/mission/. Accessed May 19, 2011.
- 30. Tierney WM, Achieng M, Baker E, et al. Experience implementing electronic health records in three East African countries. In: Safran C, ed. *MEDINFO 2010*: IMIA and SAHIA; 2010.
- Were M, Shen C, Bwana M, et al. Creation and evaluation of EMR-based paper clinical summaries to support HIV-care in Uganda, Africa. *International Journal of Medical Informatics*. 2010;79:90–96.
- 32. McNeil DG. At front lines, AIDS war is falling apart. New York Times. May 10, 2010.
- 33. Geng EH, Bwana MB, Kabakyenga J, et al. Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. *PLoS ONE*. 2010;5(11).
- 34. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. *AIDS and Behavior*. 2010;14:778–784.